2021 Investor and Analyst Day

June 3, 2021 2021 Disclaimer Investor & Analyst Day June 21 This document has been prepared by GRIFOLS, S.A. (GRIFOLS or the “Company”) exclusively for use during the 2021 Investor and Analyst Day on June 3, 2021. Therefore it cannot be disclosed or made public by any person or entity with an aim other than the one expressed above, without the prior written consent of the Company. The Company does not assume any liability for the content of this document if used for different purposes thereof. The information and any opinions or statements made in this document have neither been verified by independent third parties nor audited; therefore no express or implied warranty is made as to the impartiality, accuracy, completeness or correctness of the information or the opinions or statements expressed herein. Neither the Company, its subsidiaries nor any entity within the GRIFOLS group or any subsidiaries, the company’s advisors or representatives assume liability of any kind, whether for negligence or any other reason, for any damage or loss arising from any use of this document or its contents. Neither this document nor any part of it constitutes a contract, nor may it be used for incorporation into or construction of any contract or agreement.

IMPORTANT INFORMATION This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market Law (Royal Legislative Decree 4/2015, of 23 October, as amended and restated from time to time), Royal Decree 1310/2005, of November 4, and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any other jurisdiction.

FORWARD-LOOKING STATEMENTS This document contains forward-looking information and statements about GRIFOLS based on current assumptions and forecast made by GRIFOLS management, including pro forma figures, estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to capital expenditures, synergies, products and services, and statements regarding future performance. Forward- looking statements are statements that are not historical facts and are generally identified by the words “expected”, “potential”, “estimates” and similar expressions.

Although GRIFOLS believes that the expectations reflected in such forward-looking statements are reasonable, various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the Company and the estimates given here. These factors include those discussed in our public reports filed with the Comisión Nacional del Mercado de Valores and the Securities and Exchange Commission, which are accessible to the public. The Company assumes no liability whatsoever to update these forward-looking statements or conform them to future events or developments. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of GRIFOLS. - 2 - 2021 Investor and Analyst Day Agenda

New Business Models 3:00 - 3:05pm Welcome 5:35 - 6:05pm Daniel Fleta, Amarant Martínez, Joel Abelson Introductory Remarks Finance 3:05 - 3:15pm 6:05 - 6:25pm Raimon Grífols Alfredo Arroyo

Plasma Supply and Manufacturing Environmental, Social and Governance 3:15 - 3:35pm 6:25 - 6:45pm Eduardo Herrero Thomas Glanzmann, Nuria Pascual

Final Remarks Innovation Strategy 6:45 - 7:00pm 3:35 - 4:50pm Albert Grífols Coma-Cros, José Terencio, Karoly Víctor Grífols Deu Nikolich, Joana Sàbat, Antonio Martínez 7:00 - 7:30pm Q&A Customer Centricity 4:50 - 5:20pm Lafmin Morgan 7:30pm Closing

5:20 - 5:35pm Break 2021 Investor & Analyst Day June 21

Introductory Remarks

Building Upon Our Core Commitments

Raimon Grífols – Co-CEO

- 4 - 2021 Investor & Grifols Proved Its Resilience and Commitment in Analyst Day June 21 2020 by...

Overcoming adversity and adapting to change

2020 Expressing our gratitude to our 24,000 employees for their commitment and dedication Strengthening our commitment to patients by ensuring continuous delivery of their treatments Recognizing more than ever the generosity of donors for their ongoing contribution toward enhancing people's health and well-being Driving our expansion plan and helping countries achieve plasma self-sufficiency

Accelerating our efforts to innovate

- 5 - 2021 Investor & …and Doubling Our Efforts in Three Core Areas Analyst Day June 21

The Importance of Strengthening Our Committed to Plasma Fundamentals Sustainability

- 6 - 2021 2020: Emphasizing the Importance of Plasma Investor & Analyst Day A Global Model of Sustainable Plasma June 21

Grifols promotes Only 29% of countries obtain their hemoderivatives new business models through nationally collected plasma (WHO)

Since 2010 global plasma collections are growing but U.S. dependency has also been increasing (MRB)

In 2019, 68% of total plasma collected comes from U.S. (from the 57% in 2010) (MRB)

In Europe, self-sufficiency levels short (1) fall by 40% Joint Venture in Egypt Acquisition in Canada Strategic Alliance in China

- 7 - 1 “Plasma Flows on a Global Level: Impact and Realities in Europe” Matthew Hotchko, PhD, Marketing Research Bureau, GPS Meeting, October 28-30, 2020. 2021 Plasmatology Investor & Analyst Day First Scientific Journal Dedicated to Plasma Science June 21

Plasmatology aspires to become a scientific point of reference in the field of plasma science

It gathers all research, from basic research to clinical application

- 8 - 2021 Strengthening Our Fundamentals Investor & Analyst Day Efforts to Secure Plasma Supply and Promote Our Innovation Strategy June 21

Collaborating with national health systems to help them achieve self-sufficiency and better serve patients Consolidating our position in China, a market with Hungary tremendous growth potential 7+ plasma centers

43+ plasma Acquisition of centers remaining equity (55%) Q3 2020 +11

+7 Enhancing Egypt’s healthcare infrastructure +25 with the construction of manufacturing installations and 20 plasma centers Q4 2020 (2H 2021) Acquisition of remaining equity Q2 2021 (56%) Q1 2021

Q1 2021

Latest plasma centers transactions New business models - 9 - 2021 Grifols Continues Its Path of Sustainable Growth Investor & Analyst Day Global Century-Old Company Built On Strong Values and Ethical Principles June 21

Corporate Headquarters Barcelona Murcia 1 Bilbao Industrial Facilities San Sebastian Zaragoza 16 4 Andorra

R&D Centers

Emeryville Dublin 12 Los Angeles San Diego Montreal Leipzig Bioscience Division Düdingen Centers Denver Memphis 5 Clayton Alliance with Shanghai RAAS Raleigh-Durham Fengxian facility Diagnostic Division San Carlos Hefei Tonrol facility Centers South San Francisco Zhengzhou RAAS Haikang 8 Brazil

Hospital Division Centers Melbourne 3 Grifols affiliates Presence through Bio Supplies distributors Division Centers Operations in 100+ countries 2 Subsidiaries in 30+ countries

- 10 - 2021 Sustainability: A Strategic Pillar Investor & Analyst Day Reinforcing Our Governance and Sustainability Strategy June 21

Creation of… … to continue driving our sustainability strategy Grounded on 4 pillars Sustainability Committee

• Establish the core environmental, social and governance principles and commitments Talent Pool in our business model

• Oversee the integration of financial and Commitment with Patients non-financial information in our ESG initiatives and Donors

Sustainability Policy Social Impact

Environmental Responsibility

Integrated in our corporate strategy

- 11 - 2021 Investor & Analyst Day June 21

Plasma Supply and Manufacturing

Accelerating the Execution of Our Expansion Plan

Eduardo Herrero – President, Bioscience Industrial Group

- 12 - 2021 Investor & Analyst Day June 21

1 Plasma Operations

- 13 - 2021 Plasma Supply: Leveraging Grifols’ Competitive Advantage Investor & Analyst Day Key Drivers to Support Further Growth June 21 Strengthening a global plasma-center network to ensure plasma supply and promote long-term sustainable growth

1 2 3 Plasma Center Capacity Diversification Business Optimization

Sustainable plasma collection Strategic alliances and joint Pursuit of business growth and expansion with ventures to reinforce Grifols’ excellence through technology the highest standards of quality global expansion investments and ongoing and safety improvements

- 14 - 2021 Plasma Supply: Leveraging Grifols’ Competitive Advantage Investor & Analyst Day Multilevel Strategy to Increase Plasma Supply June 21 Volume (Liters of plasma)

Main drivers for increasing plasma supply 1 Donor Center Capacity

2 Diversification 3 Business Optimization

2019 COVID19 2020 New Centers Acquisitions Efficiencies Recovery 2021

-15% Grifols advances the execution of its expansion plan aimed at expanding its plasma collections levels: Despite a significant downturn in Q2 2020 followed by a gradual • Acquisition of plasma centers in the U.S. and EU recovery, Grifols was able to limit its • Opening of new donor centers plasma supply impact to 15% Donations per donor center increase annually as technology and standardization optimize processes

- 15 - 2021 U.S. and European Plasma Collections in 2021 Investor & Analyst Day Solid Rebound in Germany. Steady Recovery in U.S. Since April June 21

Volume (Liters of plasma)

U.S. Plasma 2021 baseline avg. collections Collections

2020 baseline avg. collections U.S. Collections vs PY20 (%) +10-20% March 31, May 31, 2021 2021 FY2021E vs. 2020A

Europe Plasma Collections 2021 baseline avg. collections

Europe Collections vs PY20 (%) March 31, May 31, 2021 2020 baseline avg. collections 2021

▪ Exhaustive safety measures to reduce donor fear factor have ▪ Plasma supply has been supported by acquisitions, new contributed to collections recovery center openings and contracts negotiations

▪ Global plasma awareness, acquisitions and donor marketing and recruitment campaigns have attracted new donor profiles - 16 - Plasma Center Business 2021 Diversification Strengthening Grifols’ Plasma-Center Network Capacity Optimization Investor & Analyst Day Advancing the Execution of the Expansion Plan June 21 Number of plasma centers • Execution plasma expansion plan 600 x3 since 2016 520 500 x2 • Number of plasma centers have duplicated over the last 5 years and 380 400 continue to grow 10 58 300 • More than 500 centers by 2025

• Expansion and diversification 200 171 plans are ambitious and represent 312 one of Grifols’ main priorities in 100 plasma supply

0 • Third-party supply agreements 2016 2018 2020 2021 2022 2024 2026 in the EU and U.S. to secure additional reliable plasma source +12% CAGR

- 17 - EU plasma centers U.S. plasma centers ROW plasma centers Plasma Center Business 2021 Diversification Global Footprint to Support Sustainable Growth Capacity Optimization Investor & Analyst Day Expanding and Diversifying Grifols’ Presence June 21 2017

Czech Republic

Canada Slovakia

United States Spain

Plasma Collection Agreements

Plasma Centers ~25 locations 190 9 locations 6 locations 18 locations

- 18 - Plasma Center Business 2021 Diversification Global Footprint to Support Sustainable Growth Capacity Optimization Investor & Analyst Day Expanding and Diversifying Grifols’ Presence June 21 2021

Czech Republic

Canada Slovakia Germany Hungary United States Spain

Italy Egypt China

Strategic Alliances and JVs Plasma Centers Agreements

Shanghai RAAS (26.2%): 370 plasma centers ~25 locations 41 plasma centers 312 48 11 locations 8 locations GEPD1 (49%): 20 plasma centers 7 3 27 locations

1. GEPD = Grifols Egypt for Plasma Derivatives 4 locations - 19 - Plasma Center Business 2021 Diversification Global Footprint to Support Sustainable Growth Capacity Optimization Investor & Analyst Day Expanding and Diversifying Grifols’ Presence June 21

Recent Plasma Supply Transactions

43 Plasma Centers Across 13 States 7 Plasma Centers in Hungary

Grifols continues to expand and diversify its U.S.- Grifols continues to expand and diversify its based plasma-center network access to European plasma adding plasma centers from Hungary Leveraging mature and licensed centers leads to an immediate increase in plasma supply This transaction strengthens Grifols’ leadership in Europe in terms of geographic scope and use Through these acquisitions, Grifols broadens its of EU-approved plasma footprint to new states and regions

- 20 - Plasma Center Business 2021 Diversification Global Footprint to Support Sustainable Growth Capacity Optimization Investor & Analyst Day Expanding and Diversifying Grifols’ Presence June 21 Strategic Alliance with SRAAS (closed in 2020) Joint Venture with Egyptian Government (2020)

No plasma centers ≤ 10 plasma centers 11 to 20 plasma centers +20 plasma centers

Bolster presence in the Middle East and Africa Access to new sources of plasma to reduce 41 centers in dependency 11 provinces on U.S. plasma

Plasma Centers CHINA SRAAS 20 plasma collection centers (1ML/year)

Operating 270(1) 38(3) Manufacturing facilities: Under Construction 20(2) 3 Total 290 41 • Fractionation plant (1ML/year Capacity) • Purification and fill-and-finish plant • Plasma and final-product warehouse • Plasma and product quality control lab Source: Reports released by manufacturers. Updated on Apr. 26, 2021 - 21 - (1)Includes 26 branch centers; (2) includes 2 branch centers; (3) includes 1 branch center Plasma Center Business 2021 Diversification Global Footprint to Support Sustainable Growth Capacity Optimization Investor & Analyst Day Diversification Supports Business Continuity June 21

Grifols Global Presence by 2022 Strategy 450 Plasma Centers1 • Global footprint and global expansion • Diversification by: 5% 10% • Opening plasma donation centers in new countries

13% • Strategic alliances • Joint ventures • Organic and inorganic growth 72% • New market opportunities • Increasing presence in the US by acquisitions and new centers USA EU China Egypt

- 22 - 1 Includes SRAAS plasma centers and Grifols Egypt (JV) Plasma Center Business 2021 Diversification Leveraging Technology to Optimize Efficiencies Capacity Optimization Investor & Analyst Day Digital Transformation June 21

Digital Transformation Benefits

Increase business process optimization while BECS Migration improving the donor experience through… • Paperless donor record • Automated manufacturing records using handheld computing devices • Streamlined process flows and reduction of manual verification steps thanks to software automation • Labor optimization via paperless and process automation Process improvements to enhance the donor experience 2020 2021 2022 2023 2024 • New plasmapheresis device to decrease the Legacy BECS New BECS donation cycle time and increase yield • Donor screening devices that reduce cycle time and allow for automated data entry

- 23 - Plasma Center Business 2021 Diversification Leveraging Technology to Optimize Efficiencies Capacity Optimization Investor & Analyst Day Integrated Technology to Enhance Donor Experience June 21

Donor Segmentation Information from nearly 1 million active donors

Plasma-center personnel engage with donors Over 220K donors registered Grifolsplasma.com in Donor Hub

+13 million emails Benefits +100k text messages and • More new donors push notifications sent • Increasing plasma donations to donors • Loyalty and satisfaction • Diversification Automated marketing • Process efficiency campaigns and multiple • Greater awareness and digital and tech tools education • Reliable and intuitive process

- 24 - Plasma Center Business 2021 Diversification Leveraging Technology to Optimize Efficiencies Capacity Optimization Investor & Analyst Day Process Enhancement June 21

One Grifols Fleet Management

• Plans to open concept • Grifols’ own production anticoagulant centers in new areas in 2021 sodium citrate is being rolled out in and beyond Grifols’ plasma-center network • Establish Grifols’ standards in • Grifols 0.9% sodium chloride is being acquired centers and used in own plasma-centers network increase average volume

Testing Optimization Talent Development

• Grifols’ lab testing capacity aligned to support growth • Academy continues to deliver virtual (36M+ samples in 2023) programs during Covid-19 • All U.S. NAT test labs in GDS • 300+ graduates from Academy’s leadership development program • Efforts to optimize testing to increase yield (2ml/donation) • 19,000+ eLearnings and 30,000 training hours since the establishment • Significant reduction test turn-around times (~48 hrs) of the Academy (2009)

- 25 - Plasma Center Business 2021 Diversification Leveraging Technology to Optimize Efficiencies Capacity Optimization Investor & Analyst Day Digital Transformation June 21

Logistics Management System Grifols Testing Lab System

• New enhanced global plasma • Consolidate all plasma laboratory management system to benefit all screening processes into one new Grifols Plasma Logistics centers corporate/global laboratory • Process optimization and greater information management system efficiencies by scaling it up across • This global system will cover end- all centers to-end plasma laboratory processes

Grifols Navigation System Artificial Intelligence

• Establish optimal levels of • Grifols’ own donor center commitment compensation software management system based on analytics and market • Manages donor center activities environment such as donor and unit suitability • Leveraging AI tools to set an and shipments adequate volume of plasma donations to meet future demand

- 26 - Plasma Center Business 2021 Diversification Leveraging Technology to Optimize Efficiencies Capacity Optimization Investor & Analyst Day Expected Improvements Derived From Business Optimization June 21

Qualified Donor Flow Time Cost per Liter1 Average Liter per Center

-10% -6% +6%

2019 2023 2019 2023 2019 2023

Qualified donor flow time expected to Effectiveness and efficiency Average liters of plasma per centers shorten as a result of new technology initiatives have led to a lower cost are increasing as a result of enhancements: per liter due to: technology to capture higher yield

• Legacy BECS transitioned out • Better balance of labor

• Electronic System Appointment • Efficiency gain in donor registration process • Donor visibility for upcoming donations • Paperless process

- 27 - 1 excludes donor commitment compensation Plasma Center Business 2021 Diversification Donor Commitment Compensation Impact Capacity Optimization Investor & Analyst Day Leveraging Other Costs June 21

Cost per Liter (CPL) Donor Commitment Compensation

Donor commitment compensation increased in 2020 to recognize donor loyalty, COVID-19 challenges and better compete in the current plasma market

Compensation increase does not imply the same increase on total cost due to the weight of different drivers

Donor commitment compensation represents ~25% of total CPL

Grifols leverages other costs in 2021 to partially offset 2019 2020 2021 the donor commitment compensation levels

Donor Commitment Compensation Other Operating Costs - 28 - 2021 Investor & Analyst Day June 21

2 Manufacturing

- 29 - 2021 Efficient Inventory Management Ensured Ongoing Operations Investor & Analyst Day Inventory Levels to Rebound in 2H 2021 June 21

Total Inventory in Liters

Thanks to strong inventory management policies, Grifols was able to build a significant stockpile of the main 4 proteins and plasma over the last 4 years and partially offset the 2020 impact

This position ensures product delivery by enabling an agile response to market variability and uncertainties

Inventory levels are expected to grow by the end of 2021

Dec-17 Dec-18 Dec-19 Dec-20 Dec-21

- 30 - 2021 Strong Inventory Position and Efficient Supply Chain Investor & Analyst Day Operations Supports Product Delivery June 21

Grifols’ Filling Operations Grifols’ Packaging Operations

Filling vials per year Packaging vials per year

+4.1% +6.2% growth growth

2017 2018 2019 2020 2021 2017 2018 2019 2020 2021

• Filling vials per year has been on the rise since 2017 • Packaging vials per year has increased since 2017

• This trend is evidence of the robust inventory • Trend continues to show strong growth management in place

- 31 - 2021 Digital Transformation 2019-2023 Investor & Analyst Day Gaining Efficiencies While Reducing Costs June 21 Robotic Process Automation (RPA)

Plant Electronic Information Batch (PI) Record (EBR) Digital Transformation

Virtual Reality

Artificial Intelligence End-to-End Planning

- 32 - 2021 Digital Transformation 2019-2023 Investor & Analyst Day June 21 2019 2020 2021 2022 End-to-End Integrated Planning (E2E) ▪ Supply chain improvement through coordination and automation of the process

Electronic Batch Record (EBR) ▪ Electronic batch record with workflow enforcement, electronic workflow for approval of batch documentation (paperless)

Plant Information (PI) ▪ Capture information across the whole site, real-time visibility across production lines

Virtual Reality ▪ Virtual reality to support industrial processes including training and virtual tours

Artificial Intelligence1

▪ Application of AI-based behavioral models and supercomputing designs to increase yield in all steps of downstream

- 33 - 1External support until 2021. To start developing internal functional capability in 2022 2021 Key Takeaways Investor & Analyst Day Accelerating the Execution of Our Expansion Plan June 21

Grifols advances the execution of Grifols continues to reinforce its Business optimization thanks to its plasma expansion and plan global plasma-center network to technology enhancements through diversified organic and secure plasma supply and support including digitalization and a inorganic growth, long-term sustainable growth fully integrated supply chain as well as optimized efficiencies

Robust inventory management Innovation-led improvements Solid recovery expected has ensured essential product will drive growth of plasma supply throughout 2021 deliveries and greater efficiencies

- 34 - 2021 Investor & Analyst Day June 21

Innovation Strategy

Expanding Our Reach: Disease Management Beyond Plasma-Derived Therapies

Albert Grífols Coma-Cros – Chief Scientific Innovation Officer Karoly Nikolich – Alkahest’s CEO José Terencio – VP Innovation Joana Sàbat – VP Bioscience Global Marketing Antonio Martínez – President Diagnostic Scientific & R&D

- 35 - 2021 Investor & Analyst Day June 21

1 Accelerating Grifols’ Innovation Through A New Leadership

- 36 - 2021 Expanding Grifols’ Global Innovation Footprint Investor & Analyst Day Setting Three Large Hubs June 21 R&D Sites 12 Hub SF Area, CA R&D sites Andorra Emeryville, Immunology San Carlos & Dublin South San 1,100+ Bioscience Düdingen, Switzerland Francisco, CA employees Diagnostic Bioscience and Diagnostic Hub Europe Hub RTP, NC Barcelona, Bilbao and +30% LA, San Diego, Research Zaragoza, Spain CA Bioscience Triangle Park, investment Bioscience and Diagnostic and Diagnostic NC last 3 years Bioscience

€1,500M+ investment over the last 5 years - 37 - 2021 Grifols’ Therapeutic Areas and Platforms Investor & Analyst Day A Pioneering Ecosystem to Promote Knowledge and New Opportunities June 21 Therapeutic Areas Innovation Ecosystem

Infectious Neurology Diseases GRIFOLS Hematology INTERNAL RESEARCH Immunology NEW Pulmonology PLATFORMS STRATEGIC Hepatology (e.g. Alkahest, ALLIANCES GigaGen) & Intensive Care Ophthalmology

INVESTED Platforms - Technologies COMPANIES INVESTIGATOR (e.g. Araclon, SPONSORED Plasma Proteomics, Fractionation & RESEARCH Immune repertoire capture and analysis AlbaJuna) Purification EXTERNAL Single-cell transcriptomics Machine learning for target discovery RESEARCH COLLABORATIONS Neuronal functional assay platform Therapeutic target selection and validation

Mammalian cell line for site-directed Polyclonal recombinant expression & integration manufacturing

Artificial Intelligence informatics Antibody therapeutics

Small molecule therapeutics - 38 - 2021 Scientific Innovation Office Investor & Analyst Day Integrating Internal and External Innovation June 21

Albert Grífols Coma-Cros Chief Scientific Innovation Officer

Vicente Blanquer Karoly Nikolich José Terencio Eva Bastida Matt Murawski Séamus McCooey VP R&D & CEO Alkahest VP Innovation, VP Scientific & VP Bioscience/ Director Global Regulatory affairs Grifols Innovation Medical Affairs Diagnostic Intellectual and New Scientific Property Technologies Development (GIANT)

- 39 - 2021 Grifols’ Innovation Ambition Investor & Analyst Day Sizable, Diversified, Steady Revenue Contribution June 21

Revenue from new product launches Patient centricity

Focus on therapeutic areas

~4% Progressively incorporating non-plasma assets to 20%+ balance our plasma portfolio

Incorporation of technological platforms which create synergies accelerating internal R&D projects

Holistic approach combining both internal and external capabilities

2020 2030 and beyond

- 40 - 2021 Grifols’ Innovation Ambition Investor & Analyst Day Sizable, Diversified, Steady Revenue Contribution June 21 By Product By Category By Source

Diversify in Non-plasma, while Accelerate investment in New Leverage External Innovation to keeping Plasma in the core Products and Indications build long-term capabilities in new fields (therapeutic areas, platforms) • Late-stage assets synergistic R&D to move focus from LCM to New Product/Indications Guidance with commercial capabilities • Licensing in & licensing out • Early-stage assets in winning platforms to build non-plasma capabilities

Non- 5% External plasma New Alkahest, 10% Product 25% GIANT 40% 50% 40% R&D New investment Indication distribution 40% Plasma Internal (includes 95% 90% Internal & 20% External) 60% Lifecycle 60% Mgmt. 35% (LCM) 30%

2015 2025 2015 2025 2015 2025 - 41 - 2021 A Pipeline to Achieve a Risk-value Balanced Portfolio Investor & Analyst Day Delivering A Comprehensive Pipeline to Support Our Patients June 21 Phase 4 / Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 LCM Regulatory Xembify® 2 GRI programs rSCIG SCIG/IVIG Europe Xembify® Immunology Spike in PdIG with IVIG-PEG SIDs-CLL ® Prefilled syringes 1 GIGA program enriched libraries (PID) Xembify Bi-weekly dose Albumin 20% FlexBag® ACLF (APACHE) US Hepatology 2 GRI programs Albumin 5% FlexBag® Decompensated EUR Cirrhosis (PRECIOSA) Alpha-1 AT Alpha-1 AT Prolastin-C® Prolastin® Pulmonology Non-cystic fibrosis 15% (SC) EUR (SPARTA) EU 4-5gr vials bronchiectasis AAT deficiency ATIII Fostamatinib*** New indication AIHA indication Haematology 2 GRI programs Fibrinogen Fibrinogen Congenital Deficiency Acquired Deficiency and severe hypofibrinogen 6 GRI programs AKST4290 Ophthalmology GIGA 564 Fibrin Sealant 3 ALK programs Biosurgery pediatric / Others Anti-CTLA-4 Oncology 2 GIGA programs & DR Use IgM Bacteremia Infectious 4 GRI programs HIV Antibody GIGA 2050 Diseases 2 GIGA programs HIV** COVID-19 GIGA 2070 COVID-19 GRF6019 ABvac40 3 GRI programs AD AD Neurology GRF6021 5 ALK programs AKST4290 PD with PD - 42 - Dementia * Alkahest; ** Project of AlbaJuna (Grifols’ invested company); *** Licensed rights from Rigel Pharmaceuticals in EU and other countries 2021 Caption Investor & Analyst Day June 21

Commercial R&D

- 43 - 2021 Investor & Analyst Day June 21

2 Changing the Course in Neurology

- 44 - 2021 Dementia: A Global Challenge, a Personal Reality Investor & Analyst Day Increasing Incidence of Dementia June 21

Dementia involves loss of memory, language, problem-solving and other thinking abilities that are severe enough to interfere with daily life

“One of the major challenges We are facing a global challenge to find a cure, of our generation” improve treatment, and ensure enough resources to enable people to live well with dementia

Dementia Incidence Worldwide Dementia Total Costs (in Million people) (in USD T)

x3 152 x2 2T

80 1T >50

2021 2030 2050 2018 2030 - 45 - Sources: WHO, Alzheimer’s Disease International, Worlds Alzheimer Report 2015, https://www.alz.org/alzheimers-dementia/what-is-dementia 2021 Slowing Down Alzheimer’s Progression: An Urgent Unmet Need Investor & Analyst th Day 5 Leading Cause of Death in the World June 21

Alzheimer’s worsens over time. It is a progressive disease , where dementia symptoms gradually worsen over a number of years No current cure, but treatments for symptoms are available and research continues

Worldwide Prevalence % of Dementia Cases By Age Mortality

>35 million Accounts for Majority are 60-70% >65y/o th patients dementia 5 leading cause cases but… of mortality 200,000 <65 y/o have younger-onset AD

- 46 - Sources: Alzheimer’s Disease International, Worlds Alzheimer Report 2015, https://www.alz.org/alzheimers-dementia/what-is-dementia 2021 Slowing Down Parkinson’s Progression: An Urgent Unmet Need Investor & Analyst Day Seeking New Mechanisms and Agents Without Burdensome Side Effects June 21

Parkinson Disease Dementia (PDD) is a complex neurodegenerative disorder where each patient experience different combination of motor and non-motor symptoms Current treatments address symptoms only and late stage pipeline unlikely to change treatments algorithm

Worldwide Prevalence Increasing Trend By Gender Total Costs >10 million Prevalence Men are $52 billion patients growing more likely /year to have PDD healthcare costs in due to aging population prevalence of dementi the U.S. a in Parkinson Disease and longer disease is close to duration 30%

x1.5

- 47 - Sources: Parkinson Foundation; Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci. 2010 Feb 15;289(1-2):18-22. doi: 10.1016/j.jns.2009.08.034. Epub 2009 Sep 4. PMID: 19733364 2021 Holistic Approach to These Urgent Unmet Needs Investor & Analyst Day Our Innovation Strategy in Neurogenerative Diseases (ND) June 21

Strategy Focus

Understanding the molecular basis of ND Diseases and those related with aging

Disease-modifying therapies Mechanism of vs. Action (MoA) Treating symptoms

Antibody, small molecules, RNA-based drugs, Products plasma-derived drugs, etc… to be developed according to the validated therapeutic target

- 48 - 2021 R&D Efforts Covering the Whole Development Path Investor & Analyst Day Our Innovation Strategy in Neurogenerative Diseases (ND) June 21 Discovery Clinical Development Programs

Plasma Fractions & Active Plasma Proteome Chronokines Two Pillar Strategy Small Molecules Immunotherapy

Understanding of plasma at the GRF-6019 Abvac40 Plasmapheresis molecular level in healthy and + disease states GRF-6021 vaccine against Ab40 Albumin replacement

Proprietary plasma fraction Placebo-controlled AB1601 inducing neurogenesis trial in 120 very early AD and Discovery of Chronokines 2 2 clinical programs MCI patients in phase II Remove toxic moieties from proteins with biological in AD and PD patients with systemic and brain compartments impact changing with age dementia in phase II Restore pharmacological properties of Albumin Expanding a pipeline of therapeutic plasma fractions, ASKT-4290 small molecules, antibodies Small molecule, antagonist of CCR3 in PD patients in phase II Explore therapeutic benefit of Reference plasma proteins in a wide range centers of CNS1 disorders

- 49 - 1 Central Nervous System; 2 Mild Cognitive Impairment 2021 Plasma Is the Body’s Highway of Communication Investor & Analyst Day The Language of this Communication Encodes Health and Disease June 21

The Balance in Plasma Proteins Determines Growth, Tissue Homeostasis, Apoptosis

We Apply Rigorous, Innovative Science to Derive Breakthrough Therapeutics from Plasma

- 50 - 2021 Plasma Is a Rich Source of Proteins With Therapeutic Potential Investor & Analyst Day We Are “Molecularizing” Plasma June 21

We have gained an unprecedented Understanding of Plasma Fractions

We identify proteins in plasma that regulate vital functions in aging and disease

1 2 3 4 Whole Fraction Plasma - 51 - 2021 Our Research Platform Investor & Analyst Day Understanding Plasma at a Molecular Level June 21

Platform Protein Validation Indication Specific Validation

Cohort & Cutting Edge Plasma Functional Readouts Fraction proteomics Neurology Single cell transcriptomics Multi Organ MoA ‘omics Ophthalmology

Imaging Frailty

Opportunistic Mechanical Allodynia (Von Frey) )

Integration with AI g

( 14

d Sham l

o 12 treatment

h Behavior Vehicle and bioinformatics s

e 10 r

h **** PF T

8 l ** rh Albumin a **** **** ****

w 6 **** a r ****

d 4 **** **** h

t *** i CCI

W 2

w

a 0 P Baseline 14 21 28 35 42 49

Days post CCI

- 52 - 2021 Plasmatology Investor & Analyst Day Innovation From Deep Analysis of the Plasma Proteome June 21

1000s of Proteins Across Alzheimer’s disease treatment with Aging & Diseases plasma protein fraction

Treatment Treatment Treatment Treatment

0.5

0

- 0.5 7597 proteoforms 7597

- 53 - 2021 Molecular Choreography of Aging and Disease Investor & Analyst Day Decoding Causal Relations of Disease Processes June 21

- 54 - 2021 Unprecedented Knowledge Base for Plasma-Derived Therapeutics Investor & Analyst Day Proteomics Lead the Way to Disease Mechanisms June 21

Best-in-class Plasma Alzheimer’s Disease Associated Proteins Proteomics

Most extensive profiling (>10,000 proteins) of healthy aging and diseases

Mass spectrometry, multiple array technologies

Plasma Fractions & Small Molecules

Differentiation between multiple diseases states (>60)

Increased interpretability of diseases by clustering - 55 - 2021 Plasma Fraction Improves Parkinson’s Disease Dementia Investor & Analyst Day Novel Therapeutic Candidates From Plasma June 21

Study Design GRF6021: D-KEFS Letter Fluency Improvement

Dosing 1 Dosing 2

5 daily Visit 5 daily Visit End of Baseline doses s doses s Study

• Dementia associated with Parkinson’s disease • Randomized placebo-controlled study • Two dosing periods of Plasma protein fraction

DKEFS Difference From Placebo Across Various Results Superior CognitiveStudies FrEffectom Basel toine tStandardo Week 24 of Care 5.3 Cognitive functions improved

Statistically meaningful differences between t 3.2 n

e 2.8 2.6

Plasma Fraction and Placebo m

e

v o

Safety and tolerability of dosing paradigm r

p

m Improvement favorable I Effect size superior as compared with currently St udy Drug used cognitive enhancer agents Rivastigmine1 Donepezil Donepezil GRF6021 Rivastigmine Do5mgnepe2zil 5mg Do10mgnepezil 120mg GRF6021

- 56 - 1 Schmitt FA, Farlow MR, Meng X, Tekin S, Olin JT. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther. 2010;16(6):330-336. doi:10.1111/j.1755-5949.2010.00182.x; 2 Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, Hsu T, Moline ML. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012 Sep 1;27(10):1230-8. doi: 10.1002/mds.25098. Epub 2012 Aug 22. PMID: 22915447 2021 Plasma Fraction Improves Mild-to-Moderate Alzheimer’s Disease Investor & Analyst Day Functional Improvements in Cognition and Daily Activities June 21

Study Design

• ADAS-cog 11 change Dosing 1 Dosing 2 from baseline • Comparison to 5 daily Visit 5 daily Visit End of Baseline doses s doses s Study historic controls

• Mild to Moderate Alzheimer’s Disease (MMSE 12-24) • Two doses: 100mL and 250mL GRF6019 • Two dosing periods of Plasma protein fraction

Results Cognitive and daily activity functions improved Safety and tolerability of two doses (100mL and 250mL per day for 5 days) favorable • Activities of daily Cognitive and functional improvements supported living (ADCS- by large number of preclinical mechanistic studies ADL23) change Additional placebo-controlled studies will be from baseline required • Comparison to historic controls Analysis of plasma fractions ongoing

- 57 - 2021 Moving Forward With the AMBAR Project Investor & Analyst 1 Day Plan to Open Reference Centers to Gather RWD on Alzheimer’s Disease June 21

Based on current AMBAR data of Plasmapheresis + Albumin replacement

Objectives Sites

To implement current AMBAR treatment in selected centers Barcelona Fundació ACE

To create Real World Data (RWD) to produce Real World Evidence (RWE)

To test the model prior to a wider spread

Site in operation Next candidate countries

1 Real World Data - 58 - 2021 Moving Forward With the AMBAR Project Investor & Analyst Day June 21

- 59 - 2021 Investor & Analyst Day June 21

3 Advancing Care in Immunology

- 60 - 2021 Primary and Secondary Immunodeficiency Driving IG Demand Investor & Analyst Day IG Replacement Therapy as the Mainstay Treatment for PID and SID Patients June 21

IG Use by Indication 2018-2025 CAGR by Indication (IG volume)3 PID and SID make up Strong growth in PID/SID, derived from increasing awareness and 48% of IG usage1 broader risk identification for PID diagnosis and new SID indications

9.3% 9.4% 9.5% 6.0% SID 8.6% 18% 8.1% 8… Others 7.1% 52% 6.4% 6.2% PID 5.6% 30% * CLL* 4 Other PID conditions

Underdiagnosed *SID to underlying disease or treatment by 50% 2 <10% eligible CLL patients receive IG therapy - 61 - 1 MRB 2018: Analysis of Ig market in the U.S. 2018 and Forecast to 2025: 2 Bousfiha et al. Primary Immunodeficiency Diseases Worldwide: More Common than Generally Thought. J Clin Immunol. 2013; 33:1-7; 3 Internal Estimate ; 4 Chronic Lymphocytic Leukemia 2021 Expanding IG Replacement Therapy to Thousands of CLL Patients Investor & Analyst Day CLL is the Fastest Growing Patient Segment for IG Therapy June 21

U.S. CLL Patients Forecast 4 (in Thousands) HGG1 occurs in up to 85% of patients with CLL (due to 80.000 2,3 malignancy itself and/or treatment) 70.000 +12%

Associated with a high rate of infections 60.000 that account for >60% mortality 50.000

40.000

Program to include both IVIG and 30.000 SCIG for CLL SID U.S. indication. Unique for SCIG 20.000 10.000

Opportunity to add clinical evidence to 0 differentiate IG portfolio in markets with approved SID indications

Expected launch: 2026 CLL patients prescribed IG therapy expected to grow significantly

- 62 - 1 Hypogammaglobulinemia; 2 Friman V et al. Hematol Oncol. 2016;1-12: doi 10.1002/hon.2323 [Epub ahead of print]; 3 Seppänen M. Clin Exp Immunol. 2014;178(Suppl 1):10-13; 4 Internal data 2021 High Market Potential for Gamunex® and Xembify® in CLL Investor & Analyst Day Offering CLL Patients Flexibility in Site of Care June 21

Leukemia Cases U.S. CLL IG Market Potential (in €)

U.S. ~4% Leukemia CLL of IG sales >1bn Prevalence 38% x4 376,508

262m

2021 2031

- 63 - https://www.lls.org/facts-and-statistics/facts-and-statistics-overview/facts-and-statistics 2021 Improving Flexibility and Convenience Investor & Analyst Day Offering a Better Home Treatment Experience June 21

Xembify® Pre-filled Syringes Xembify® Biweekly Dosing

Ideal for self-administration (manual push) and Adds flexibility with new dosing regimen option compatible with infusion pumps Faster infusion rate (60ml/h) Ease of use and time-saving process

Accurate pre-measured dosing Opportunity to individualize dosing frequency

Potentially helping to reduce medication errors Potential improvement in patient quality of life

Reduces medical supply waste

Expected launch: 2023 Expected launch: 2024

Offering broader administration options provides a greater opportunity for treatment satisfaction and patient empowerment, which may support high levels of patient compliance - 64 - 2021 Advancing Towards Cutting-Edge Delivery Systems Investor & Analyst Day Smart Pump System June 21

Improving IVIG & SCIG home infusion treatment experience

Simplify the infusion process, improve ease of use, and add mobility/freedom

Bluetooth connectivity to an app/dashboard

Superior features over disposable wearable devices

Expected launch: 2023

Opportunity to leverage digital health platform to improve patient outcomes

- 65 - 2021 Investor & Analyst Day June 21

4 Shaping Cirrhosis Management in Hepatology

- 66 - 2021 Combination of Acute Treatment and Long-Term Albumin Use Investor & Analyst Day Our Cirrhosis Management Perspective June 21 Decompensated Cirrhosis

High prevalence Quality of life is 2 >14.5 million often poor patients1 Multiple organ failure + Systemic inflammation High burden for Resolution Regression patients, caregivers and society

Total Costs Grifols extensive research and >$9.5 billion clinical program with innovative /year in the U.S.3 Liver transplant is the only procedure Albumin treatment approaches available today to avoid offers opportunities to patients by further complications and slowing disease progression and death bridging for liver transplant

- 67 - 1 Internal estimates; 2 Acute on chronic liver failure; 3 Volk et al. Hepatol. Comm. VOL. 4, NO. 8, 2020 ​ 2021 Shaping the Future of Albumin Investor & Analyst Day Our Innovation Strategy in Hepatology June 21 Key discoveries in understanding Albumin Albumin’s therapeutical potential Most abundant protein in the body Focus of investigation Albumin infusion shows clinical for more than 15 years Albumin is improvement in Investigations widely used as a decompensated 4 into albumin’s Clinical & non-clinical program volume Albumin is cirrhosis potential use as to understand Albumin’s role in health and disease replacement/ shown to be a drug in and MoA expander fluid as altered in Plasma Protein complex a volume disease2,3 Replacement diseases are replacement/ with albumin these investigations… underway expander fluid1 may provide benefits across Concept of albumin as a pharmaceutical different with a multifactorial Mechanism of diseases5,6 Action

(focusing in hepatology and other diseases like Alzheimer)

- 68 - 1 Vincent JL et al. Crit Care. 2014;18(4):231; 2 Garcia-Martinez R et al. Hepatology. 2013;58(5):1836-46; 3 Costa M et al. J Alzheimers Dis. 2018;63(4):1395-404; 4 Caraceni P et al. Lancet. 2018; 5 Boada M et al. Alzheimers Dement (N Y). 2019;5:61-9; 6 Laleman W et al. Can J Gastroenterol Hepatol. 2018;2018:1027152 2021 Exploring the Full Potential of Albumin Investor & Analyst Day More Than Just a Volume Expander June 21

Main transporter (fatty acids, drugs, metabolites, metals, Aβ1)

Maintains Main extracellular intravascular volume antioxidant Free radical scavenger2

Most abundant Immunomodulatory protein effects3 (Plasma & CSF)

- 69 - 1 Biere AL et al . J Biol Chem. 1996;271:32916–32922; 2 Colombo G et al. Antioxid. Redox Signal. Dec 2012.1515-1527.http://doi.org/10.1089/ars.2012.4702; 3 Casulleras M et al. Sci. Transl. Med. 2020; Vol. 12, Issue 566, eaax5135 2021 Albumin Acts as a Multi-Target Disease-Modifying Agent Investor & Analyst Day Its Function Correlates With Clinical Outcomes in Advanced Cirrhosis June 21

Baseline Along Treatment

[Alb] [Alb] Alb transport Disease Disease Alb transport severity Alb oxidation severity Alb oxidation Alb glycation Albumin treatment

* Decompensated Cirrhosis & ACLF

- 70 - Sources: Horrillo et al. J. Hepat. 73:S756; The International Liver Congress. August 25-28 2020 ; Horrillo et al. The international Liver Congress. June 23-26 2021 (Abstract accepted); Oettl et al. J Hepatol. 2013 Nov;59(5):978-83; Baldassarre, et al. Hepatology 2021 Mar 12 2021 Extensive Clinical Program Investor & Analyst Day Albumin Treatment at Different Stages of Cirrhosis June 21

Compensated Decompensated Advanced chronic liver ACLF Transplant or cirrhosis cirrhosis disease (10-35y) (30 day) death (10-15y) (2-4y) 3

Multiple organ failure + Systemic inflammation

Resolution Regression

Translational research LTA1 with Albumin 20% (hyperoncotic) Plasma Protein Replacement plus Albumin 5%

- 71 - 1 Long-Term Albumin Use 2021 PRECIOSA Study: LTA Admin. to Revert Cirrhosis Progression Investor & Analyst Day Prevention of Mortality in Subjects With Decompensated Cirrhosis and Ascites June 21

Phase 3 1:1 Randomized SMT 410 subjects with decompensated cirrhosis and ascites (12 months follow-up) International / SMT + Albumin 20% Open label Multi-center (1,5g/kg bw every 10 ± 2 d)

Centers and Countries Status (Apr 2021)

~40 participating centers • Est. study end (LPLV): Q1 2023 • Recruitment update: 129 subjects randomized (31%)

U.S., Canada, Belgium, Denmark, France, Germany, Italy, Spain and UK - 72 - 2021 APACHE Study: Bridging Therapy to Liver Transplant Investor & Analyst Day ALADDIN Study: Understanding Disease Pathogenesis and PE-A 5% MoA June 21

Effects of Plasma Protein Replacement with Human Serum Albumin 5% (PE-A 5%) on Short-term Translational research project supporting Survival in Subjects with "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality Apache, aim to provide key insights on ACLF and Albumin MoA Plasma Protein Remove endogenous / exogenous toxic Replacement substances and damaged albumin

Improvement of Albumin levels and anti-oxidant Therapeutic 5% Albumin Mechanism of systemic PE A-5% and transport functions inflammation, organ mechanism failure and ACLF in of action in cirrhosis ACLF Design Centers Status (Apr 2021)

Ph3, 1:1 randomized, 40 centers from US and 8 EU • Est. study end (LPLV): 2Q multicenter, open label enrolling countries 2022 380 ACLF subjects (90 days • Recruitment update: 109 N = 250 patients from EU participating in APACHE FU): SMT vs SMT + PE A-5% subjects randomized (29%) (59 randomized (24%), April 2021)

- 73 - 2021 Capturing the Opportunity in Cirrhosis Investor & Analyst Day Long-Term Albumin Use June 21 2 out of 3 HCP1 Global Opportunity likely to prescribe LTA to prevent decompensations >14.5 million according to ANSWER study data patients (Market research 2020) Improved overall Reduced cost of Positive impact survival by +38% hospitalization on quality of life 8-10% target target population2 Progressive adoption expected as new Total % Adoption evidence is provided If ONLY 10% of patients were treated based on Innovator Early Early Late Laggards s Adopters Majority Majorit key for LTA wide adoption y PRECIOSA protocol

x100 x100 higher albumin x +15% consumption with of current Preciosa Protocol >€400 Albumin compared to acute uses market x million Acute use Chronic use - 74 - 1 Healthcare Practitioners; 2 Decompensated cirrhosis with ascites and treated by specialist excluding 20% of patients receiving HCV treatment 2021 Investor & Analyst Day June 21

5 Thriving Against Infectious Diseases

- 75 - 2021 Leverage Our Learnings From Prior Efforts Investor & Analyst Day Permanent Threat of Emerging Pathogens Calls for Developing New Therapies June 21

Emerging Infectious Diseases (EID) Deaths

Issue of global concern as incidence has The number of deaths from outbreaks recorded in the last increased dramatically in recent years two decades shows the big impact of infectious disease Transmission and spread at an 3,530,58 unprecedented speed influenced by human-related factors1 2 11,325 Globalization Climate change Human-wild animal interface Antimicrobial resistance Host susceptibility Behavior changes 813 812 284 76

SARS Influenza A MERS EBOLA ZIKA SARS-CoV-2 H1N1

2002-2003 2009-2010 2012 2014-2016 2015 2019-2021

1Journal of Physiological Anthropology volume 39, Article number: 29 (2020); 2 https://www.who.int/csr/sars/country/2003_07_11/en/; 3The Lancet Infectious Diseases, 12(9), 687-695. doi:10.1016/S1473-3099(12)70121-4; 4 https://www.ecdc.europa.eu/en/middle-east-respiratory- - 76 - syndrome-coronavirus-mers-cov-situation-update; 5https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html; 6https://apps.who.int/iris/bitstream/handle/10665/204348/zikasitrep_5Feb2016_eng.pdf;jsessionid=2E8C110C039D151C1EE6B384A9F064A8?sequence=1; 7WHO 2021 Plasma and Recombinant Polyclonal Immunoglobulins Platforms Investor & Analyst Day Our Innovation Strategy in Infectious Diseases: Passive Immunization June 21

Address diseases caused by Focus on development of IgM products to boost the unmet and emergent pathogens Polyclonal immune system hyperimmune globulins against specific pathogens

2 Technological platforms

1 2 Plasma polyclonal Recombinant hyperimmunes from polyclonal hyperimmunes using convalescent or vaccinated GigaGen technology donors

2 (IV and SC) GIGA-2050 Anti-COVID-19 Anti-COVID-19 to be used in prophylaxis or early first polyclonal recombinant diagnosed patients hyperimmune to be tested in humans

- 77 - 2021 Plasma Polyclonal Hyperimmunes Platform: Anti-COVID-19 Investor & Analyst Day Leveraging Our Capabilities to Fight Against an Emergent Pathogen June 21

10% Hyperimmune globulin IV 20% Hyperimmune globulin SC

INSIGHT 012/OTAC C19-IG Study to evaluate its Safety and Efficacy in non- Study to evaluate the safety and efficacy in infected hospitalized patients with COVID-19 asymptomatic ambulatory outpatients

Target population Non-hospitalized patients age ≥ 55 Target population with COVID-19 who have had COVID- Ambulatory Asymptomatic patients 19 symptoms ≤ 5 days with confirmed SARS-CoV-2 infection

Platform built from our vast experience in developing immunoglobulins from selected donors against specific pathogens

- 78 - 2021 Recombinant and Polyclonal Hyperimmunes: GigaGen Platform Investor & Analyst Day Boost a Novel Method to Generate a Wide Range of Immunoglobulins June 21 = x Trillions Immune repertoire Capture Re-create

Unlimited quantities of Patented microfluidics, the new class of molecular biology, and therapeutic can be made cell engineering from a few donors with processes potent antibody responses

Antibodies can be Donors can be engineered for high humanized mice, potency, immune vaccinated donors, or effector activity, long convalescent donors half-life

- 79 - Keating et al., Nature Biotechnology, 2021 2021 GIGA-2050 Allows Clinical Validation of the GigaGen Platform Investor & Analyst Day >12,000 Anti-Coronavirus Antibodies Captured From 16 Convalescent Donors June 21

Manufacture as a recombinant monoclonal antibody Live SARS-CoV-2 Virus Neutralization (rMAB), regulatory framework generally followed standard rMAB

Drug product has 100- Acute monkey toxicity study showed no drug-related fold higher potency events at the highest dose tested (475 mg drug / kg body than convalescent plasma from the same weight) donors

IND reviewed by FDA with no clinical holds

Clustergram of Antibody Sequence Diversity First dose in Phase I clinical study: enrollment ongoing

Enrichment for neutralizing antibodies Sorting for binders to SARS-CoV-2 RBD, and removing antibodies that don’t bind, reduces diversity but enriches neutralizing titer

- 80 - 2021 Grifols, in the Fight Against Pandemic Investor & Analyst Day Commitment With Society and the World, Preparing for Future Challenges June 21

as vaccination progresses number of COVID-19 new cases is expected to be significantly reduced in developed economies with massive access to vaccines

Vaccination is still Grifols is committed to well below society to keep working herd immunity targets >14 million to bring new therapies (25% of US population new COVID-19 cases won’t be vaccinated*) in 2022

Not all countries have broad access to vaccines COVID-19 is devastating in countries like India New variants that might become resistant to vaccines

- 81 - Source: KFF Covid-19 vaccine monitor: KFF COVID-19 Vaccine Monitor Dashboard | KFF 2021 Investor & Analyst Day June 21

6 Ophthalmology: Expanding Into a New Therapeutic Space

- 82 - 2021 New Avenues for Research in nAMD and Diabetic Retinopathy Investor & Analyst Day Entering Into a New Therapeutic Space June 21

Neovascular Age-Related Macular Degeneration (nAMD) Diabetic Retinopathy (DR) 2

Most common Leading cause of blindness Diabetes Prevalence aged >60 microvascular complication of x1.6 Current treatment: Intra-Vitreal Injections (IVT) Diabetes 629M Expensive & burdensome >400 M Significant challenges 1 Treatment cost 2 Not all patients respond to treatment 3 Frequent office visits 2021 2045 4 Poor adherence due to complex drug regimens 3.2 million estimated to be visually impaired Outcomes are well as a consequence of DR below RCTs1 in real world practice Early detection and treatment prevent 50%- 70% of its associated blindness

- 83 - 1 Randomized Controlled Trial; 2 Joseph M. Coney, MD Am J Manag Care. 2019;25:S311-S316​ 2021 AKST4290: Blocking Eotaxin-Mediated Inflammation Investor & Analyst Day Potent CCR3 Inhibitor for Multiple Therapeutic Indications June 21

Chronokine Target: Eotaxin Receptor (GPCR): CCR3 Therapeutic Treatment: AKST4290 Normalization of Inflammatory & Increased in Age & Disease In Eosinophils, Endothelial cells, T cells & Monocytes Immunomodulatory Cascades

200 Decreased Infiltration of Immune

150 Cells (macrophages, t-cells, eosinophils)

100

Protein LevelProtein Reduced microgliosis

50

0 20 40 60 80 Downregulated Inflammatory Age (years) 0 Cytokines

- 84 - 2021 Blocking Eotaxin-CCR3 Signaling Reduces Retinal Inflammation Investor & Analyst Day Addressing AMD and Diabetic Retinopathy June 21

Eotaxin/CCR3 Binding increases

Photoreceptors Membrane Permeability/Degradation

Immune Cell Recruitment

RPE Cytokine Upregulation Bruch’s

Choroid

Heightened Neuroinflammation & Neurodegeneration Sclera

Eotaxin Bound CCR3 Eosinophil Immune Cell VEGF TNFa/ IL17 … Macrophage Microgliosis

- 85 - 2021 AKST4290 Reduces Inflammation in the Eye Investor & Analyst Day New Insights Into the Pathology of Eye Diseases: Cytokines and Immune Cells June 21

Inflammatory Proteins from Circulating Plasma Accumulate in the Eye

RANTES/CCL5 MIG/CXCL9 *** AKST4290 Reduces 3 *** 8 *** * *** ** Inflammatory Proteins and 6

2

L

L

m

m /

/ 4 Infiltrating Immune Cells in

g

g p 1 p 2 the Eye 0 0 e 3 0 e 3 0 l 9 l 9 ic IO 2 ic IO 2 h a 4 h a 4 e N + e N + V 3 V 3 IO IO a a N N

+ Monocytes CD4 T cells Neutrophils Myeloid Cells **** **** **** 8000 **** 2000 **** ** 250 **** **** 200 *** *** **** ** * 200

1500 150

s

s

l

s

s

l l

l 150

l

l

l

l

e

e e

e 4000 1000 100

C

C

C

C

100

#

#

# # 50 500 50

0 0 0 0 e 3 0 e 3 0 le 3 0 e 3 0 l O 9 l 9 c O 9 l O 9 ic I 2 ic IO 2 i I 2 ic I 2 h a 4 h a 4 h a 4 h a 4 e N + e N + e N + e N + V 3 V 3 V 3 V 3 IO IO IO IO a a a a N N N N

2020

- 86 - 2021 Positive Phase 2a in Age-Related Macular Degeneration Investor & Analyst Day nAMD Patients Treated With Oral AKST4290 June 21

Change in BCVA from Baseline

Naïve patients (201) Mean (Median) N (%)

Overall BCVA Gain +7.0 (8) 29 (100%)

“Responders” ≥5 Letter BCVA Gain +14.9 (11.5) 16 (55%)

≥10 Letter BCVA Gain +17.3 (15.5) 12 (41%)

≥15 Letter BCVA Gain +23.2 (22) 6 (21%)

RPE-DH Change -79.3 (31) 19 (66%)*

CST Change -13.9 (-4) 29 (100%)

* 19 of 29 subjects with RPE Detachment

Strong improvement in Best Corrected Visual Acuity: similar to standard of care aVEGF1 injections into the eye Oral agent a substantial advancement compared to the high treatment burden of current intravitreal aVEGF

- 87 - 1 Vascular Endothelial Growth Factor 2021 Diabetic Retinopathy: A Major Unmet Medical Need Investor & Analyst Day An Oral Treatment Would Be Highly Desirable June 21 Manifestations of DR Characteristics and Progression of DR

Phase 2 study in Diabetic Retinopathy (DR) with AKST4290

• CAPRI: A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy • N = 80; Randomization = 1:1 (AKST4290 400 mg BID: placebo to match); at 25 US sites • Dose = 400mg BID (orally) for 24 weeks treatment • Rationale: AKST4290 improved vision in AMD patients and may also have a similar effect in DR • Anti-inflammatory activity of the compound would slow or block the progression of the pathology of DR

- 88 - 2021 Meeting the Challenge and Addressing the Opportunity Investor & Analyst Day Entering a Large and Growing Market June 21

Neovascular Age-Related Macular Degeneration (nAMD) Diabetic Retinopathy (DR)

1.5x 2.4x $7.9 $8.6 billion >1.5 million billion treated >3.2 million $5.3 billion need treatment Continues to increase due to advancing age of the general population $3.6 billion

A preventive treatment could reach an even broader population

2018 2025 2019 2029 Data from US, EU4, UK, JP, Australia and China Data from US, EU4, UK and JP

- 89 - Source: Global data, nAMD and DR Global Drug Forecast and Market Analysis 2021 Investor & Analyst Day June 21

7 Continuous Developments in Diagnostics

- 90 - 2021 Diagnostics R&D Areas of Focus Investor & Analyst Day Proteins June 21

Immunohematology Clinical Diagnostics DG Gel SARS CoV2 Antibody Test CE Marked New Antisera development Promonitor – Biological Drug Monitoring New gel card DG Gel DC Scan Plus testing Promonitor Quick Anti-IFX & IFX Multicard Promonitor Quick Anti-ADL & ADL Extended phenotyping

Drug Interference Solution Kit to resolve daratumumab interference for Recombinant Proteins cancer patients Grifols Portfolio (internal customers) Immunoassays for donor screening Screening/Diagnostics Therapeutics • IAs for Donor Screening • Alkahest Ultrasensitive SMC Assays in development • Immunohematology (Neurodegeneration) • Biosciences (SARS- Discriminatory Multiplex: HIV/HCV, HBsAg CoV2) CDMO Opportunities (external customers) HBcore Chagas HTLV Syphilis CMV HBsAg Confirmatory

High throughput analyzer in development

- 91 - 2021 Contract Development & Manufacturing at Grifols, Emeryville Investor & Analyst Day Recombinant Protein Excellence in Microbial and Mammalian Systems June 21 Broad Range of Services for Therapeutic and Diagnostic Projects

Molecular and process design to Research make novel proteins Combining the Chiron legacy of recombinant expression innovation Assay development to with Grifols quality and excellence support new medicines Development Process development and optimization to improve yields and Current Active Projects generate efficiencies

Material production for toxicology, Orphan drugs Production formulation studies, clinical trials Vaccines and GMP commercial production Wound healing Continually expanding and adding new capabilities… Therapeutic enzymes • New Pilot Plant for scale-up and GxP material production • New hosts to expand options in mammalian and yeast expression • New single-use equipment for fermentation and purification - 92 - 2021 Diagnostics R&D Areas of Focus Investor & Analyst Day Nucleic Acids June 21

NAT Donor Screening Lab Automation Panther ART: to support greater lab automation and efficiency

Improved middleware

Other New Procleix® Assays Babesia assay: CE Marked (Jan 2021)

Plasmodium assay: in development

New Multiplex Procleix® Assays UltrioPlex® E assay

ArboPlex® assay

- 93 - 2021 New Multiplex Assays for NAT Blood Screening Investor & Analyst Day New Solutions to Enhance Testing Efficiency and Blood Safety June 21

Assays on Procleix® Panther system recently launched or under development Procleix® UltrioPlex E assay: results for 5 viruses into single reaction: HIV-1, HIV-2, HCV, HBV, and HEV HIV-1 HIV-2

Procleix® ArboPlex Assay: results for 5 arthropod-borne viruses (or “arboviruses”) into a single reaction: West Nile, Usutu, chikungunya, dengue, and Zika viruses HCV HBV

Other multiplex assay concepts in feasibility HEV IC

Multiplex format offers significant advantages to both customers and Grifols

Increases laboratory efficiency:

• Same labor and instrument needs for delivery of more results faster • No need to manage multiple assay kits; reduction in waste (tips/other disposables and liquid waste)

Increases production efficiency by combining manufacturing operations

- 94 - 2021 Diagnostics R&D Areas of Focus Investor & Analyst Day Nucleic Acids June 21

NAT Donor Screening Clinical Diagnostics Lab Automation Infectious Diseases Panther ART: to support greater lab automation and efficiency Procleix® SARS-CoV-2 assay

Improved middleware

Other New Procleix® Assays Babesia assay: CE Marked (Jan 2021)

Plasmodium assay: in development

New Multiplex Procleix® Assays Ultrio® Plex E assay

ArboPlex® assay

- 95 - 2021 Grifols Diagnostics Rapid Response to Pandemic Investor & Analyst ® Day Procleix SARS-CoV-2 Assay Developed in <3 Months June 21

Highly sensitive and specific detection of SARS-CoV-2 RNA

CE marked: May 2020

Assay runs on fully automated Procleix® Panther system Among most sensitive EUA NATs according to results from testing FDA SARS-CoV-2 Reference Panel SARS-CoV-2 Our ultra-high sensitivity and long experience in donors testing allows testing in pools of samples improving efficiency

Over 10 million tests manufactured in San Diego

Test is widely used in select EU under license agreement and U.S. markets

EU1: as an aid in diagnosis of COVID-19 (respiratory specimen testing)

US: organ/tissue donor screening to support transplant safety

® Grifols’ employee testing Procleix Panther System

- 96 - 1 Under a license agreement with a third party 2021 Collaboration Made SARS-CoV-2 Assay Project a Success! Investor & Analyst Day June 21

R&D Sites

Hub SF Area, CA Andorra Emeryville, Immunology San Carlos & Dublin South San Bioscience Francisco, CA Düdingen, Switzerland Bioscience Diagnostic and Diagnostic Hub Europe Hub RTP, NC Barcelona, Bilbao and LA, San Diego, Research Zaragoza, Spain CA Bioscience Triangle Park, Bioscience and Diagnostic and Diagnostic NC Bioscience

- 97 - 2021 Diagnostics R&D Areas of Focus Investor & Analyst Day Nucleic Acids June 21

NAT Donor Screening Clinical Diagnostics Lab Automation Infectious Diseases Panther ART: to support greater lab automation and efficiency Procleix® SARS-CoV-2 assay

Improved middleware Specialty/Genetic Testing Other New Procleix® Assays Development of GRIFOLS Genetic Babesia assay: CE Marked (Jan 2021) Service for A1AT Deficiency testing, direct to patients (Over- Plasmodium assay: in development The-Counter)

New Multiplex Procleix® Assays UltrioPlex® E assay

ArboPlex® assay

- 98 - 2021 Expanding AlphaID™ Testing to OTC Consumer Program Investor & Analyst Day Gain FDA Clearance for AlphaID™ at Home June 21

AlphaID™ At Home Genetic AlphaID™ At Home Saliva A1AT Genotyping Test Genetic Health Risk Health Risk Service Website Collection Kit for OTC Service Result Report

Order online AlphaID™ Use AlphaID™ At Home Ship saliva Access report online via at Home Saliva Collection Kit at collection device secure patient portal home with collected sample to lab

Over-the-Counter (OTC) Innovative Solution to expand the U.S. screening program

- 99 - The OTC At Home Service is in the design and development stage 2021 AlphaID™ at Home Genetic Health Risk Service Investor & Analyst Day User Comprehension Study Overview June 21

Stage 1 Stage 2 Stage 3 Stage 4

Nov 19 Feb 20 Dec 20 May 21 Jul 21 Ad Board FDA Presub

Refine Result Reports to Test Result Reports & Finalize Result Reports & User Comprehension improve comprehension Questionnaires Comprehension Study Protocol Study

Two rounds of interviews Stage 4: 500 interviews x 80 interviews 125 interviews • 100 individuals x report • Representing U.S population

• 4 batches of 10 individuals • Pilot study of stage 4 Educational moduleEducational • Retrospective think-a-loud • Representing U.S population interviews comprehension score • Michigan area ≥90% for each domain • Online interviews (pandemia) Purpose Results Limitations

Next Steps 5 Types of Types reports5

- 100 - 2021 Our Goal Remains Firm Investor & Analyst Day Accelerate Diagnosis to Stop Genetic Emphysema’s Progression June 21

is helping to accelerate diagnosis and is the basis for innovative testing strategies

Grifols WW Testing Program

>850,000 >190,000 >15,000 tests deficient patients severe patients Alpha-1 patients performed found diagnosed remain undiagnosed >90%

- 101 - 2021 Continuous Developments in Alpha-1 Diagnosis Investor & Analyst Day Self-Testing Will Provide Benefits for Patients and HCPs June 21

Self-Testing, Multiple Benefits

Patients HCPs

Maximize DTC Reduce Alpha1 campaigns potential screening workload Allows for further developments that would accelerate testing by better Empower Enable addressing customers needs COPD Telemedicine related patients tools

Simplify Alpha- Facilitate familiar 1 Dx process screening

- 102 - 2021 0-500M 500-1,000M 1,000-3,000M >3,000M USD Market Size Opportunity USD USD USD Investor & Analyst Day For Selected Projects June 21

Product Indication Market Size

Immunology SCIG / IVIG SIDs-CLL

ACLF Hepatology Albumin LTA Cirrhosis

Pulmonology Alpha-1 AT Non-CF Bronchiectasis

Fostamatinib AIHA Haematology Fibrinogen Acquired Deficiency ATIII New indication (each) HIV Antibody HIV Ophthalmology AKST4290 nAMD & DR / Others GIGA 564 Anti-CTLA-4 Oncology (each) Infectious IgM Bacteremia Diseases GIGA2050 COVID-19 GRF6019 Alzheimer’s Disease AKST4290 Parkinson’s Disease with Dementia Neurology ABvac40 Alzheimer's’ Disease (each) GRF6021 Parkinson’s Disease - 103 - 2021 Key Takeaways Investor & Analyst Day Expanding Our Reach: Disease Management Beyond Plasma-Derived Therapies June 21

Executing on our Innovation Focus on high prevalence and New leadership and governance Strategy within and outside the transformational therapies that to effectively foster and support plasma space to achieve a more meet global challenges with huge breakthrough innovation risk-value balanced portfolio untapped potential

Transforming disease management Exploring large opportunities on in Neurology, Ophthalmology and Strengthening pipeline in plasma: sharpen focus on CLL; Infectious Diseases through Diagnostic across the value chain shaping cirrhosis treatments and innovative platforms led by and new diseases accelerating alpha-1 diagnostic Alkahest and GigaGen

- 104 - 2021 Investor & Analyst Day June 21

Customer Centricity

Showing Strength and Successfully Managing Adversity

Lafmin Morgan – Chief Commercial Officer

- 105 - 2021 Pandemic Impact on Healthcare Investor & Analyst Day Short-Term Impacts Continue in 2021, but Receding June 21

Healthcare Hospitals & Commercial Patients Providers Institutions Interactions

Diagnosis visits remain Biopharma in-person Perceived value of 1-1 VC 12% below 2019 baseline, patient visits were up 17% Lab testing (all settings) vs. in-person has fallen; both generating a -3,8% gap in in March’21 with all still below 20192 1 Specialists and PCPs now Px specialties increasing1 want more in-person1 Elective procedures still The pandemic could cause remain 15% below 2019 Total prescriptions U.S. hospitals to face levels1 recovering compared with between $53 billion and Total Biopharma details 2020 (+6%)1 $122 billion in revenue loss increased 13% in March’21 this year3 rising to 93% of baseline1

- 106 - Sources: 1 IQVIA data published April 2021; 2 IQVIA data published September 2020; 3 Hospital finances in 2021: 10 things to know (www.beckerhospitalsreview.com) 2021 Pandemic Impact on Healthcare Investor & Analyst Day Patients Are Facing Additional Challenges June 21

Alpha-1 patients PID/SID patients ITP patients COVID-19 patients

Patients at increased risk of COVID-19 severe illness coping with additional challenges on top of their conditions…

Follow up and Isolation and Therapy administration monitoring: labs tests, Uncertainty follow up visits. Etc.

- 107 - 2021 Pandemic Impact on Healthcare Investor & Analyst Day Providing Support, Bringing New Therapies and Looking for New Solutions June 21

Alpha-1 patients PID/SID patients ITP patients COVID-19 patients

Patient Support Programs Launch of Tavlesse® just Development and launch Xembify® launch in the US (US, EU and LATAM) after COVID-19 wave 1 of TMA in <3 months

Continuous support to R&D of therapies to fight Home Infusion patients groups against COVID-19

AlphaIDTM in patient hands

- 108 - 2021 Demonstrating Resilience and Commitment to Sustainable Growth Investor & Analyst Day Increasing Our Revenues in This Extraordinary Context June 21

(EUR in millions)

5,340 5,099 Contributions from new products 4,487 4,318 >50% revenue growth 4,050

2016 2017 2018 2019 20202020

- 109 - 2021 Continue Introducing Innovations to Address Customer Needs Investor & Analyst Day Contributions From New Products >50% of Revenue Growth in 2020 June 21

ULTRIO PLEX E

FlexBag

• New flexible container to complement vials and broaden Grifols offering to customers • US launch in 2021

- 110 - 2021 Investor & Analyst Day June 21

1 Bioscience

- 111 - 2021 Robust Demand and Launch of New Products Bolster Bioscience Investor & Analyst Day Revenues Reach EUR 4,241M With a 8% CAGR June 21

(Sales and % growth vs. PY)

Sustained Quarter over 8.9% 7.5% Quarter growth for more than 8.0% 6.8% 7.9% 40 consecutive quarters

2016 2017 2018 2019 20202020

- 112 - 1 Growth at constant currency 2021 Investor & Analyst Day June 21

Long Term Trends Continue to Support the Return to Strong Growth

- 113 - 2021 Pulmonology: Our Goal Remains Firm Investor & Analyst Day Accelerate Diagnosis and Stopping Genetic Emphysema’s Progression June 21

is helping to accelerate diagnosis and is the base for innovative testing strategies

Grifols WW Testing Program

>850,000 >190,000 >15,000 Alpha-1 patients deficient patients severe patients tests remain undiagnosed found diagnosed performed >90%

- 114 - 2021 Immunology: The First Step to Help Patients is Diagnosis Investor & Analyst 1 Day NIH Estimates 500,000 Undiagnosed PIDD Patients in the US June 21 DIAGNOSIS

Average PIDD diagnosis still takes 12.4 years2

~400 Important burden genetic defects for the healthcare 1 ~250,000 responsible for PIDD2 system diagnosed with PIDD Undiagnosed PIDD $102,736 3 Incidence of Diagnosed PIDD 1:1200 1 in 2000 $22,696 live births5

Grifols is uniquely positioned to leverage our expertise in IG replacement therapy and diagnostics to improve the rate and time to an appropriate PIDD diagnosis

- 115 - 1 Modell V. Immunol Res. 2007;38(1-3):43-47; 2. Routes J, et al. J Clin Immunol. 2016;36:450-461. 3Boyle JM, Buckley RH. J Clin Immunol. 2007;27(5):497-502; 4 French MA, Tangye SG. J Infect Dis. 2019;jiz230. doi:10.1093/infdis/jiz230; 5 Bonilla FA, et al. J Allergy Clin Immunol. 2015;136(5):1186-1205.e1-78 2021 Immunology: SID Market Keeps Growing Investor & Analyst Day Significant Room to Continue Helping Patients with SIDs June 21 NEW USES AND INDICATIONS SID market continues to grow in hematological malignancies and beyond

Driven by… Increased use of SID-inducing medication in both oncological and autoimmune indications

Extended survival rates of cancer patients 2018 2025

Chronic Lymphocytic Leukemia (CLL) and Hypogammaglobulinemia (HGG)

Most common type Grifols has a clinical of leukemia in adults HGG occurs development plan for HGG CLL in up to 85% of and CLL, as part of our 38% patients at some point (due to malignancy itself continued commitment to and/or treatment)2,3 SIDs patients

Infections are major cause of death in 25% to 50% of patients with CLL3

- 116 - 1 US PPTA Distribution Data;; 2 Friman V et al. Hematol Oncol. 2016;1-12: doi 10.1002/hon.2323. [Epub ahead of print]; 3 Seppänen M. Clin Exp Immunol. 2014;178(Suppl 1):10-13. SID: Secondary Immune Deficiency (not an FDA approved indication in the U.S.) 2021 Intensive Care and Hepatology Investor & Analyst Day The Use of Albumin in Liver Disease Will Become a Key Growth Driver June 21 NEW USES AND INDICATIONS

2019 Albumin Category Use Albumin use in Hepatology (%)

Hepatology >50%

22%

Italy

highest albumin consumption per capita driven by Albumin Chronic use adoption in decompensated cirrhosis

There is no treatment for decompensated cirrhosis other than liver transplant

- 117 - Sources: Internal data 2021 Immunology and Neurology Investor & Analyst Day IgG per Capita Consumption Growth in the Coming Years June 21 EXPANSION

Raising awareness on PIDD Growing uses and diagnosis and treatment indications in SIDs

2013-2020 per capita consumption (g/000 Population) for top markets worldwide

Global IgG average per capita 350 consumption is still far from 300 reaching its full potential 250 200 150 100 50 0

2020 2013

- 118 - Sources: MRB & International use 2021 Xembify®, Expanding Grifols IG Portfolio Investor & Analyst Day Aiming to Meet the Large, Unmet Medical Need in PIDD June 21 NEW PRODUCTS Xembify® U.S. Sales Volume Since Launch

Xembify® sees growth in Q1 2021 through an accelerated base of patients and Prescribers prescribers, paving the way for continuity and further adoption in 2021

90% 10-15% of Grifols global IG sales will be Xembify® of Xembify® prescribers Dec Mar continue to 2020 2025 2021 prescribe

Patients

85%

of Xembify®

Jul-20

Jan-20 Jan-21

Jun-20

Oct-20

Apr-20

Sep-20

Feb-20 Feb-21 Dec-20

Dec-19 patients that

Aug-20

Nov-19 Nov-20

Mar-20 Mar-21 May-20 Dec Mar start, continue 2020 2021 treatment - 119 - Sources: Internal data 2021 Pandemic Has Not Been an Obstacle Investor & Analyst Day Continue to Bring New Therapies for Chronic ITP Patients* June 21 NEW PRODUCTS Tavlesse® GER Sales Volume since Launch

Tavlesse® has been successfully launched in Q3 2020 in UK and Germany

Achieved targets Continuing through to Q1 2021 for P&R1 process UK and Germany in Germany

Continuing HTA2 and Launch timelines in subsequent progress for further 8 reimbursement in UK EU countries in Q3 and Q4 2021 Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9

- 120 - Sources: Internal data; * ITP Patients who are refractory to other treatments; 1 Price and Reimbursement ; 2 Health Technology Assessment 2021 Investor & Analyst Day June 21

Addressing Customer Needs Strengthening Our Market Position

- 121 - 2021 Maintaining 2nd Market Position in IVIG and IVIG+SCIG Market Investor & Analyst Day Delivering on Our Promises June 21

In the face of increasingly tough competition Xembify® launch and customer centric (SCIG products) years ago we committed to developments will allow us to keep strengthening keep outperforming our market position

Grifols IVIG growth vs. SCIG + IVIG market growth (‘15-’19) CAGRs

(in Million grams) 50 300 45

40 250 249 35 232 200 30 213 199 We maintain our 25 184 166 150 nd 20 2 Market

15 100 position in 10 50 5 the IVIG market and 0 0 even considering the 2015 2016 2017 2018 2019 2020 IVIG + SCIG market

Total Market IVIG+SCIG Grifols

- 122 - Sources: Internal data 2021 Alpha-1 Strong 70% Market Share Despite of Years of Competition Investor & Analyst Day Our Solid Customer Centric Mindset is Key June 21 A strong customer centric mindset has permitted Grifols to improve market share in the middle of the global pandemic

Testing Continued Reliable Supply Patient Support Innovation

Alpha-1 antitrypsin Market 2020 Sustained and reliable product supply Important Alpha-1 product shortage from competitor in Q4’20 - Q1’21 challenged treatment continuity of hundreds of patients in EU during pandemic Grifols

>70% Grifols, the Global Alpha-1 leader, was ready to immediately put in place all efforts thus guaranteeing therapy to patients

- 123 - Sources: Internal data 2021 Alpha-1 Strong 70% Market Share Despite of Years of Competition Investor & Analyst Day Our Solid Customer Centric Mindset is Key June 21 A strong customer centric mindset has permitted Grifols to improve market share in the middle of the global pandemic

Testing Continued Reliable Supply Patient Support Innovation

Patient disease management programs provide personalized care and home infusion, a vital resource during COVID-19

Ensuring treatment continuity with Home Infusion services

Supporting beyond treatment…

Psychological Virtual Virtual support monographic meetings with trainings on HCPs and other “new normality” patients

- 124 - 2021 Alpha-1 Strong 70% Market Share Despite of Years of Competition Investor & Analyst Day Our Solid Customer Centric Mindset is Key June 21 A strong customer centric mindset has permitted Grifols to improve market share in the middle of the global pandemic

Testing Continued Reliable Supply Patient Support Innovation

We offer multiple Alpha-1 testing solutions, addressing different customers needs when they more need it

1991 2013 2018 Alphakit™ online Finger stick Alphakit® AlphaID™ AlphaID™ orders grew dry blood spot QuickScreen Cheek Swab approved to be significantly in used in patients 2020 hands under HCP supervision (Spain)

- 125 - 2021 Novel Partnership Journey to Build on Complementarity Investor & Analyst Day June 21

2016 2020 First meeting VistasealTM U.S.: Launch between completed Grifols & 2018 2022 TM Ethicon Joint product/project VistasealTM – OUS launch Vistaseal launches Successful wet development work complete lab testing of continues 2nd Ethicon Plasma VeraSeal® Protein - FDA approval Fibrin Sealant capacity expansion

VistasealTM U.S. market Agreements launch Globalization of signed 2019 VeraSeal ® 2017 2021

&

- 126 - 2021 Investor & Analyst Day June 21

2 Diagnostic

- 127 - 2021 The Diagnostic Division Reported €776M Over 2020 Investor & Analyst Day Sustainable Growth Over the Last 5 Years June 21

(Sales and % growth vs. PY)

Strong resilient businesses

COVID-19 TMA test addressing a medical emergency 1.1% 7.3% 0.7% -3.9% 6.8% Grifols continues to extend partnerships with top customers in the world (Korean Red Cross)

2016 2017 2018 2019 20202020

- 128 - 2021 Global Leader in Blood Donor Screening Investor & Analyst Day Plasma Testing Poised for Strong Growth June 21

Blood donations tested Plasma donations 70+ donations tested We are converting all every minute with Grifols testing locations to ® a Procleix assay* Procleix® Instruments and Assays

Recent plasma center 200+ acquisitions fueling growth 36M people impacted prospects every minute*

- 129 - Source: Internal Data; * Does not include plasma collections 2021 Milestones and Innovations for Our Customers Investor & Analyst Day Our Innovation Strategy Delivering on the Future Needs of Transfusion Patients June 21

Panther® Art Ultrio® Plex E Babesia Menu Expansion

HIV-1 ARBOVIRUSES HCV HEV HBV ZIKA WNV HIKUNGUNYA HIV-2 C DENGUE USUTU

PLASMODIUM

Complement Tests

- 130 - 2021 Customer Value Marketing – UltrioPlex E Investor & Analyst Day Making an Impact in Blood Banks Operation June 21

48% 40% Hepatitis E virus (HEV) is one of the leading causes of acute viral Reduction of Free Floor NAT Tests Lab Space hepatitis worldwide

HEV-RNA screening of blood donations implemented 8% 40% in eight EU countries Faster Release of Free Floor Incidence of HEV infection Results and Save Costs in Europe over 10 years has grown by ten times 45% 50% 48%

Free-up Lab Staff Gain Storage Reduce 20M Space Environmental Impact HEV INFECTIONS WORLDWIDE 45% 40% 48%

Reduction of Lab Save Energy Go Green - 131 - Staff Costs and Save Costs 2021 Laying the Foundation to Become a Leader in Immunohematology Investor & Analyst Day Strong Resilience in Spite of a Global Pandemic June 21 Execution based on 4 main pillars

Customer Sales force Portfolio Manufacturing centric focus expansion enhancement footprint

Focus Market share R&D focus to Manufacturing particularly after growth enhance the portfolio capacity for sales support of instrument and strategic markets reagents - 132 - 2021 Execution Focused on Customers Continues to Fuel Growth Investor & Analyst Day Continuous Success Across All Customer Segments With Highest Customer Loyalty June 21

Instruments placements Customer retention rate Comprehensive Portfolio 700+ +96% Erytra-Eflexis® Erytra-Eflexis® Since launch on Q2 2017 Since launch on Q2 2017

Opportunities Competitive conversions 180+ +55% Opportunities Won in 2020

- 133 - 2021 Investor & Analyst Day June 21

3 Hospital

- 134 - 2021 Weathering the Storm in 2020 Investor & Analyst Day COVID-19 Challenges Impacted Performance With a Few Important Exceptions June 21

MedKeeper Sales

(Sales and % growth vs. PY) Hospitals have been significantly impacted by COVID-19 driving decline in Hospital Division revenues in 2020

Pharmatech business was impacted with complex projects being delayed. As a result, Pharmatech revenue declined 21.0% 11.8% in 2020 after two consecutive 47.6% 10.0% years of strong double digit growth 57.0%

2017 2018 2019 2020

PharmacyKeeper achieved strong growth in 2020

- 135 - 2021 Providing Life-Sustaining Products and Technology for Patients Investor & Analyst Day and Pharmacy Solutions During the Pandemic June 21

We remain a leader for IV Fluids in Iberia, helping to ensure hospitalized patients receive needed sterile IV solutions

Grifols rapidly implemented medication control technology in new treatment centers deployed during the outbreak in Spain

In the U.S., 93,000 compounded sterile preparations are made every day with the help of PharmacyKeeper

When significant logistical challenges arose for distributing vaccines within hospitals PharmacyKeeper enhanced its industry award winning* IVWF software, to help optimize dispensing for patients

- 136 - *KLAS Category Leader for IV Workflow Management five consecutive years 2021 Investor & Analyst Day June 21

4 Bio Supplies

- 137 - 2021 Bio Supplies Diversifies the Revenue Base Investor & Analyst Day Successful Business Expansion Over the Last 4 Years June 21

(Sales and % growth vs. PY) Provide additional value to Grifols products

Vertical Integration supporting 67% Grifols divisions

Become a leading supplier of 47% Biological Materials for the IVD Industry 206% 41% -20%

2016 2017 2018 2019 20202020

- 138 - 2021 Bio Supplies Commercial Grows by Double Digits Investor & Analyst Day Building the Pillars to Assure Excellence in Long-Term Partnerships June 21

Biopharma Diagnostic

Provide additional value to Grifols Vertical integration for Diagnostic IH by supplying blood proteins in niche markets components as raw material while providing additional value to non-suitable for fractionation plasma

High growth expectations driven by…

Several companies New industry using Grifols excipients applications for current New products in clinical trials portfolio

- 139 - 2021 Key Takeaways Investor & Analyst Day Showing Strength and Successfully Managing Adversity June 21

Grifols grew in 2020, with 50% Customer and patient contribution to growth from Long-term trends remain centricity has allowed us to new products and achieving robust for Bioscience be prepared for the future 40 consecutive quarters growing QoQ

Bio Supplies is a growing Long-term trends also Demonstrated ability to high-margin business, support growth in succeed in competitive significantly contributing to the Diagnostic and Hospital markets development of new drugs and divisions products

- 140 - 2021 Grifols, Along the Journey Investor & Analyst Day Grifols is Uniquely Positioned to Help Patients and HCPs Along All the Way June 21

Commitment 25% 7/10 with patients with blood donations in N.A of CIDP patients 190k+ decompensated liver are tested using systems AATD diagnosed cirrhosis rely on Grifols patients worldwide and assays developed by Grifols Diagnostics

- 141 - 2021 Investor and Analyst Day

June 3, 2021 2021 Investor & Analyst Day June 21

New Business Models

Advocating Patients' Needs Through a Sustainable Global Plasma Model

Daniel Fleta – Chief Industrial Officer

- 143 - 2021 Global Dependency on U.S. Plasma Investor & Analyst Day June 21

+149% (in M Liters)

46,254

2010 2019

18,613 +115% North North +20% America America 68% 12,131 57% 9,134 7,619 +132% -68% 5,634

296 686 520 165 North America Asia Pacific Europe Middle Latin America East/Africa

2010 2019

U.S. plasma collections are increasing at a faster rate than the global market

- 144 - Source: MRB 2019 Global Blood & Plasma Collections Report 2021 The U.S. Leads Global Plasma Collections Investor & Analyst Day June 21 Plasma Collections Liters per 1,000 (M L/year) population Population (M)

U.S. 45.9 138.7 331.0

Austria, Czechia, 5.2 46.1 112.8 Germany, Hungary

Rest of Europe 3.9 6.1 634.3

Canada* 0.3 8.8 37.7

China 8.9 6.2 1,433.8

Egypt - - 100.3

Sources: “UN World Population Prospects 2019 Data Booklet”; “Plasma Collections 2019” and “MRB 2019 Global Blood & Plasma Collections Report.” - 145 - Calculation from “Protecting Access to Immune Globulins for Canadians: Final Report of the Expert Panel,” Health Canada, 2018. 2021 Global Dependency on U.S. Plasma Investor & Analyst Day June 21

2018 IgG Plasma Usage vs. Plasma Collected (millions of liters)

Plasma 41.8 surplus:

15.2 United European +57% Reliance on the U.S. to meet demand States Union

Plasma 14.5 shortage

-38% 5.5 26.6 14,5 9.0

Plasma collections Internal demand Internal demand Plasma collections

If current landscape remains unchanged, the plasma surplus will grow in the U.S. while deficits will increase in other regions, particularly in Europe

- 146 - Source: “Plasma Flows on a Global Level: Impact and Realities in Europe,” Matthew Hotchko, PhD, Marketing Research Bureau, GPS Meeting, October 28-30, 2020. 2021 Higher Demand for Plasma Driven by Healthcare Systems Investor & Analyst Day Development, New Indications and Higher-Prevalence Diseases June 21 Worldwide Prevalence* Diagnosis and prescriptions Hematology Pulmonology are increasing Coagulation Factors Alpha-1 • Hemophilia • Alpha-1-antitrypsin deficiency Albumin – Alzheimer’s and Cirrhosis • Von Willebrand disease

People with People with +1.1M Haemophilia1 +185k severe AATD2

Cirrhosis & Sepsis Immunology & Neurology Ig – Secondary Immunodeficiencies (i.e. Oncology) Albumin Immunoglobulins • Chronic liver disease & cirrhosis • Exposure to rabies, tetanus, • Sepsis hepatitis A / B • General and cardiac surgery • PIDD - Primary immunodeficiency • Others including plasmapheresis, burns disease • CIDP - Chronic inflammatory demyelinating polyneuropathy Other indications People with +14.5M cirrhosis3 Fight emerging virus i.e. Ebola, COVID-19 People with PIDD4 People with +6M +49M sepsis5

*Total Prevalence calculations over 5,360,680 World Population >18years – Source UN World Population Prospects 2019_DataBooklet. - 147 - 1 World Federation of Haemophilia; 2 Grifols patient counts (last update 10MAY2020): assume 50% of patients diagnoses receive treatment based in market knowledge and affiliate input. COPD Prev 10-18%. COPD, Diagnosis 10-50%; 3 Burden of Cirrhosis on Patients and Caregivers, 2020; ; 4 National Institute of Allergy and Infectious Diseases. Primary immune deficiency diseases (PIDDs). niaid.nih.gov/diseases-conditions/primary-immune-deficiency-diseases-PIDDs Accessed June 30, 2020; 5 https:/ww.who.int/news-room/fact-sheets/detail/sepsis 2021 Grifols Value Proposition for Plasma Self-Sufficiency Projects Investor & Analyst Day Exceptional Synergies to Unlock the Potential of Strategic Projects June 21

Know-how Commitment & Reliability Agility & Flexibilty

Tech.Transf. & EPCM Capabilities Patients at the Core Local Presence, Global Reach Grifols Engineering Safety & Quality Long-term Partner Unique Approach to Geographies

• Multidisciplinary and highly qualified • Commitment to patients extending • Geographically focused strategy team providing complete turnkey access to plasma therapies worldwide • Partners as diverse as needed: Private solutions from conceptual design to • Products quality and safety are in the or public sector facility management and operation foreground built on the solid foundation • China Affairs Office: a successful model • Proprietary technology development of a reliable plasma supply • Optimization of CAPEX and control of • Comprehensive portfolio of products cost, timing and quality and instruments to ensure quality; from plasma testing solutions to DC consumables manufacturing

- 148 - 2021 Investor & Analyst Day June 21

Egypt

Clearing the Path Towards Self-Sufficiency

Daniel Fleta – Chief Industrial Officer

- 149 - 2021 Egypt at a Glance 2020 Investor & Analyst Day June 21

Median Age 2019 Plasma Derived Products Market value $m Revenues 102 million inhabitants 45 40 5.6 14% 12.0 29% Population growth 2 M/year 25

23.5 GDP growth 57% 3.6%

Source: Egyptian Ministry of Planning and development Egypt EU US IVIG Albumin Pd FVIII

Source: MRB THE PLASMA PROTEINS MARKET IN EGYPT 2019

- 150 - 2021 Strengthening Egypt’s Healthcare System and Self-Sufficiency Investor & Analyst Day Grifols Engineering, Industrial and Quality Expertise Offer a Unique Opportunity June 21

• Identification of plasma- Benefits derivatives as a strategic Strategic alliance Egypt asset for the country between Grifols and Free up plasma and manufacturing • Improve Egypt’s the Egyptian healthcare system government will help capacity the country attain self- Additional plasma sufficiency of plasma- procurement sources derived medicines • Know-how and technology Expansion and enable market opportunities in other • Operations management expansion in the territories (Africa, Saudi Arabia, Kuwait, Qatar, • Quality and safety Middle East Bahrain, United Arab Emirates, Oman, Iraq, Jordan, Lebanon, Syria and Yemen) • Training and Africa

Grifols will have total management oversight for the design and construction of facilities, operations, quality and safety to guarantee self- sufficiency of world-class plasma products - 151 - 2021 Egyptian Plasma-Center Network Investor & Analyst Day June 21

- 152 - 2021 October 6th Plasma-Donor Center Investor & Analyst Day June 21

Plot area: 5,100 m² • Paved area: 2,763 m² • Green area: 500 m² • Footprint main bldg. and ancillary: 1,836 m² Scope Donor center, plasma testing labs, plasma freezers warehouse, - 153 - Grifols Academy for Plasmapheresis and plasma ops. offices 2021 Egyptian Manufacturing Site Investor & Analyst Day Medical City Development Plan in New Capital City June 21

New Capital City Highlights

Size 170,000 Acres

Fully digitalized & connected to Industrial Zone

Green city: Max. 40% bldg. 60% green field

- 154 - 2021 Manufacturing Site Location Investor & Analyst Day June 21

Capacity 1 Million Liters of Plasma (expandable) Fractionation, purification and fill-and-finish of: Scope • Coagulation factors • Gammaglobulins Plasma logistics center, labs, vivarium, R&D, common - 155 - • Albumin areas, warehouses, utilities and manufacturing plants 2021 Manufacturing Plant Investor & Analyst Day June 21

27,000m3

8,500Tn

322,500m3

105,000 m2 Side View - 156 - 2021 Key Takeaways Investor & Analyst Day Clearing the Path Towards Self-Sufficiency June 21

Higher demand of PDMP Egypt offers growth potential Global plasma collections are due to healthcare systems as a fast-growing and growing but the U.S. development, better diagnosis, developing nation and dependency is also new indications and clinical leading regional supplier to increasing trials to treat high-prevalence the Middle East and Africa diseases

Clear willingness of the Grifols Industrial through Egyptian government to set Free up plasma and Grifols Engineering is a legislative framework manufacturing capacity uniquely poised to offer that promotes the viability and to serve other growing markets cutting-edge turnkey solutions sustainability of this project

- 157 - 2021 Investor & Analyst Day June 21

China

Progressing on Our Strategic Alliance Under a Successful New Business Model

Amarant Martínez – VP China Affairs Office

- 158 - 2021 Great Potential on a 10-Year Horizon Investor & Analyst Day At the Forefront of Global Health Spending June 21

Plasma Protein Market in 2019 Global Health Spending: 2020 vs. 2030

USD 27.3 billion USD Tr CAGR20-30 16.9 World +6.2%

RoW 25% 9.3 +3.7 T China USA 46% 17% +11.4% France 3% +1.9 T 3% 10% US Japan 35% 5% +4.5% 42% +2.1 T Germany China 18% 2020 2030

China is the only country expected to achieve double-digit growth over the next 10 years

- 159 - Source: Grifols Global Plasma Database (excl. recombinant) and Fitch Solutions. 2021 SRAAS Successfully Weathered COVID-19 Investor & Analyst Day Limiting Plasma Collections Impact to -2.0% vs. -9.3% of the Industry June 21

Plasma Collections by Company in 2020 Overall Industry Plasma Collections (‘000L)

10000 +6.9% -9.3% Boya China continues working Others 8,949 390 9000 towards self-sufficiency Pac. 8,388 8,113 370 as a long-term objective

Shuanglin 8000 7,833 -2.0% 350 7000 We expect a steady Hualan 330 6000 increase of registered CNBG 310 donors and number of 5000 plasma centers CBPO 290 14.4% 4000

263 270 Ongoing reforms to ease 3000 256 restrictions on household 244 246 250 2000 registration (Hukou) has #2 in China the potential to expand 1000 230 +100 bps vs 2019 donor base

0 210 41 plasma centers 2017 2018 2019 2020 38 plasma centers + Collections SRAAS Collections ex-SRAAS 3 under construction Plasma centers (2 centers opened in last 6 months) - 160 - Source: Reports released by listed manufacturers 2020. Internal Analysis. 2021 Sustained Double-Digit Growth Adds USD 500M+ Each Year Investor & Analyst Day Leveraging Our Capabilities to Become Leaders in Albumin and IG June 21 Albumin (tons) IG (tons)

MNCs1 Domestic +14.6% +13.0% +15.9% 2 +11.7% 5.1% MS2 35 2 620 30 16.8% 535 (+20.2% YoY) 28 27 26 465 (+73.3% YoY) 411 22 393 18 327 16 263 287 13.8% (+42.8% YoY)

2013 2014 2015 2016 2017 2018 2019 2020 2013 2014 2015 2016 2017 2018 2019 2020

pdFVIII (M IU) Fibrinogen (kg)

+20.8% +27.5% +25.0% +60.3%

426 699 1 1 339 334 35.7% 32.9% 483 471 445 267 436 (+60.5% YoY) 218 (+80.7% YoY) 167 152 252 113 147 178

2013 2014 2015 2016 2017 2018 2019 2020 2013 2014 2015 2016 2017 2018 2019 2020

- 161 - 1 Multinational corporations; 2 Market share; Source: Institutes of Food and Drug Control. 2021 Bioscience Commercial Platform Under SRAAS Investor & Analyst Day From Third-Party Distribution Model to Strategic Partnership With Leading Manufacturer June 21 Key Features Execution in 2021 Q1 Q2 Q3 Q4 January Biddings transition Full commercial strategy at play Integrated commercial platform SRAAS and 1st batch release Direct-to-customer model appointed as exclusive April distributor + First product shipment Control of sales flow and channel + Agility Seamless operational transition completed with NO supply disruption

Contributing to Comprehensive portfolio + Full geographical reach, extensive coverage & expanded customer base

11 categories • Commercial team: 250+ FTEs Albumin FVIII • Direct Sales & Distribution Management • Hyperimmunoglobulins marketed directly to IVIG PCC the CDCs IMIG Fibrinogen • 500+ Commercial Partners Hep B IG Thrombin • 6,500+ Retail Pharmacies

Tetanus IG Fibrin Sealant • 700+ Grade III Hospitals • 2,500+ Grade II Hospitals Rabies IG - 162 - 2021 Fastest Growing IVD Market With Great Potential Investor & Analyst Day Implementing the Go-Direct Model June 21

In-Vitro Diagnostics Market

USD 1st step: Reorganization of internal operations by shifting from current partners towards integrated 30 28.1 8% 26.9 7.0% commercial model 7% 25 22.9 6% 20 4.9% Phased implementation of NAT solutions at 4.6% 4.5% 5% 4.2% SRAAS facilities (pool of 96) 3.8% 15 4%

3% 8.8 10 8.1 Portfolio expansion under assessment: 6.9 6.9 2% 5.64.9 • Ultrio Plex E (HEV, HIV-1, 4.0 5 3.8 3.2 2.6 2.2 2.7 2.5 2.1 2.6 1% HIV-2, HCV, HBV)

0 0% • New DG Gel Cards US Japan China Germany Italy France

2019 2020e 2025e CAGR ('20e-'25e)

Advancing towards a Diagnostic integrated model for blood and plasma screening

- 163 - Sources: IVD Market Report, Markets and Markets, May 2020. 2021 China: A Dynamic Innovation Ecosystem Investor & Analyst Day Capitalizing on New Opportunities June 21

“2021-2030 Alzheimer's Disease 2020 2050 Prevention and Treatment Work >10M patients >30M patients Plan” • Center of Excellence at Great Bay Area, partnering with To reach highest rate of: AD prevention leading institutions. Concept matches with country approach and treatment awareness rate; services network; elderly cognitive function • Group of Experts screening rate • Clinical Program to generate real-world data and address aspects of indications, reimbursement and guidelines

Centralized Successful SRAAS Pilots Supporting authorities according to Provincial Health with Grifols’ full-range Testing Commission requirements capabilities

SRAAS development of IVIG R&D 10% and SCIG 20%

​Take Innovation Beyond Others Plasma to China

- 164 - Sources: Chinese Aging Well Association-Alzheimer Branch; Jian Kang Shi Bao. 2021 Key Takeaways Investor & Analyst Day Progressing on Our Strategic Alliance Under a Successful New Business Model June 21

Continue delivering on Unparalleled growth Excellent performance amid execution in the second year potential across divisions these challenging times of the alliance

Robust capabilities and broader portfolio through Advancing towards a Innovation as a key element the integrated Bioscience Diagnostic integrated model within the alliance commercial platform under SRAAS

- 165 - 2021 Investor & Analyst Day June 21

Canada

Leveraging Our Experience and Capabilities to Meet the Needs of National Customers

Joel Abelson – President Bioscience Commercial

- 166 - 2021 Grifols is Well-Positioned to Meet Canada’s Needs Investor & Analyst Day June 21

Only large-scale domestic manufacturing facility and Deep experience in the uniquely positioned for Canadian market, with continued growth across full more than 30 years as the platform of service offerings Grifols is supporting primary fractionator for Canada’s path Canada’s blood operators towards self- sufficiency by Grifols Montreal Facility partnering with Canadian Blood Services to enhance security of supply in a novel proof-of- One of the highest IG The pandemic heightened concept partnership usage per capita with one the urgency for plasma self- of the lowest plasma sufficiency/domestic model donation rates production

- 167 - 2021 Building On A Legacy Investor & Analyst Day Over 30 Year History as the Primary Fractionator for Canada’s Blood Operators June 21 Canada’s Blood Operators Canadian Plasma Proteins Market1 Canadian Blood Services and Héma-Québec USD 582 million • Accountable to Canadians for a safe, secure blood system vWF • Funded by the provincial and territorial Ministries of Health AAT 2.2% 2.7% • Responsible for procurement of plasma derived medicines Domestic

C1 16% (21.9%) Total Population IG 37.7 million 60.4% Grams of IG distributed by Others Blood Operators 23% 9.6% 9,150 kg Héma-Québec Québec Albumin 3.2% 29%

71% 77% Canadian Blood Services (CBS) Héma-Québec All regions except Québec Canadian Blood Services

Source: Market research Bureau, Canada 2019/20, Statistics Canada - 168 - 1 Without recombinant factors (period 2019/20) 2021 Plasma Opportunity in Canada Investor & Analyst Day One of the Highest IG per Capita. One of the Lowest Plasma Donation Rates June 21 Canada is one of the highest users of Ig per capita… … but has one of the lowest plasma donation rates

243g per 1,000 population (CBS figures) 8.8L collected per 1,000 population (2017 data) IG grams shipped and rate of sufficiency Liters collected per 1,000 population 7,000,0007.000.000 25% United States: 113 L Austria: 75 L 6,000,0006.000.000 Czechia: 45 L 20% Germany: 36 L Spain 8 L 5,000,0005.000.000 Canada 8.8 L 15% 4,000,0004.000.000

3.000.000 3,000,000 10%

2,000,0002.000.000 5% Canada 1,000,0001.000.000

0 0% 2013-2014 2014-2025 2015-2016 2016-2017 2017-2018 2018-2019 2019-2020

IG grams shipped Sufficiency rate

• Canada’s plasma volumes sent for fractionation are Risk modeling suggests 50% primarily from recovered plasma target for IG sufficiency to meet needs of critical patient groups • Few source plasma (apheresis) collection centers (for which no alternative exists) 13.7% 21.7% have been established (non-remunerated model)

Sources: Bédard, J.P. (2020) “Navigating Complexity: Ensuring Security of Supply.” Canadian Blood Services, Jaworski, P. (2020) “Bloody Well Pay Them: The Case for Voluntary Remunerated Plasma.” - 169 - Adam Smith Research Trust, Medical Research Bureau, Canada 2019/20. Calculation from ‘Protecting Access to Immune Globulins for Canadians – Final Report of the Expert Panel. Health Canada. 2018. 2021 On the Path Towards Self-Sufficiency Investor & Analyst Day Enhancing Domestic Supply Security Through Partnership With CBS June 21

Kelowna, British Columbia State-of-the-art plasma donor center opens in Sudbury Media Release December 16, 2020

“Through a unique consultative partnership, we have had the opportunity to learn from the best practices Grifols has refined to improve and streamline our plasma collections Lethbridge, Alberta in our new plasma donor centres. As the national blood authority, Canadian Blood Services will continue to deliver on our mandate to support patients by operating the national blood system guided by the principles outlined by Justice Horace Krever.” Sudbury, Ontario Jean-Paul Bédard, Vice-President Plasma Operations, Canadian Blood Services

Sudbury’s center is the first of three new Canadian Blood Services dedicated plasma-donor centers that “Grifols, with more than three decades providing trusted plasma medicines to are opening across Canada. First announced in Canadians, is extremely pleased to deepen its relationship with Canadian Blood Services August 2019, these donor centers represent a proof- to expand Canada’s plasma-collection infrastructure to meet the growing demand for of-concept approach aimed at offering an optimized plasma therapies and enhance the health and quality of life of the Canadian patients who collections model that leverages Canadian Blood depend on them.” Services’ extensive expertise and industry best Joel Abelson, President Grifols’ Bioscience Commercial Division practices for plasma collection.

- 170 - Sources: Media Release, December 16, 2020 “State-of-the-art plasma donor centre opens in Sudbury. Canadian Blood Services 2021 Key Takeaways Investor & Analyst Day Leveraging Our Experience and Capabilities to Meet the Needs of National June 21 Customers

For 30+ years, Grifols has Grifols’ is committed to Strengthening Grifols’ been the primary fractionator helping countries reach self- presence in Canada, building of Canadian plasma under sufficiency of plasma- on a legacy of partnership in contract manufacturing derived medicines Canada’s blood system services

Market opportunity as Uniquely positioned for demand continues to grow and Only large-scale domestic continued growth across full IG use per capita is one of manufacturing facility platform of service offerings the highest in the world

- 171 - 2021 Investor & Analyst Day June 21

Finance

Driving Resource Allocation to Support Further Growth and Profitability

Alfredo Arroyo – Chief Financial Officer

- 172 - 2021 Investor & Analyst Day June 21

1 Delivering on Our Commitments

- 173 - 2021 Delivering on Our Commitments Investor & Analyst Day 2020 IAD Key Takeaways June 21

Reinforcing our international Increasing plasma supply Driving long-term sustainable expansion through SRAAS in through organic and inorganic growth across all divisions China and alliances in Canada initiatives and Egypt

Integrated innovation efforts Continuous CAPEX to Deleveraging and securing as a core strategic pillar support future growth liquidity remain key priorities

- 174 - 2021 Delivering on Our Commitments Investor & Analyst Day 2020 IAD Key Takeaways June 21

Driving long-term sustainable Reinforcing our international Increasing plasma supply growth across all divisions expansion through SRAAS in China through organic and and alliances in Canada and Egypt inorganic initiatives €m Revenues 4.500 Since last IAD… +7% +7% Since last IAD… 4.000 Hungary 3.500 +7 plasma +4% centers 500 +41% +4% 2016 2017 2018 2019 2020 U.S. Egypt +43 plasma +20 plasma centers Bioscience Diagnostic Bio Supplies Hospital centers (opening in 2H 2021)

Integrated innovation efforts as Continuous CAPEX to support Inorganic a core strategic pillar future growth Organic growth growth Efficiencies €1,500m+ in innovation over the last 5 years €1,400m+ in CAPEX over the last 5 years (15-20 new plasma 329 332 311 308 centers in 2H) 294 291 298 268 271 252 Deleveraging and securing liquidity remain key priorities (March ‘21 up to EUR 1bn+)

2016 2017 2018 2019 2020 2016 2017 2018 2019 2020

- 175 - 2021 Investor & Analyst Day June 21

2 Proven Resilience During Unprecedented Times

- 176 - 2021 Proven Resilience During Unprecedented Times Investor & Analyst Day 2020 COVID Impacts June 21 Revenues (€M) Most significant impacts on EBITDA 2020 (€M)

5,340 5,099 + - 4,318 4,487 4,050 Cost containment plan +112 Sub-activity costs -205

NAT COVID test +49 Lower Bioscience sales -111

EUR -155m 2016 2017 2018 2019 20202020

EBITDA Reported (€M) Impact in P&L 2020

1.600 COVID Impact 30% EBTIDA 1.400 EBITDA Margin 155 30% + - 1,434 1.200 1,324 29% 1,219 1,223 • Bioscience topline 1.000 1,141 29% • Price increases

800 28% (mid-single digit growth) performance impacted in 28.2% 28.2% 28.1% 600 28% Q4 by lower plasma 27.7%1 • 50% of revenue growth 400 27% collections 27.3% from new product launches 200 27% • Cost per liter increase 0 26% 2016 2017 2018 2019 20202020

- 177 - 1 Excluding COVID-19 impact on EBITDA and considering reported sales 2021 Proven Resilience During Unprecedented Times Investor & Analyst Day 2021 COVID Impacts June 21

Estimated Impact in P&L for 2021

+ -

• Price increases (mid-single digit growth) • Bioscience topline performance impacted • Product mix including recent product launches by lower plasma collections • Expected sales rebound in the last part of 2021 • Cost per liter increase derived from higher thanks to sustained solid demand and recovery in donor fees and fixed costs under absorption plasma collections • R&D efforts stemming from the integration and • Optimization and efficiencies: Continuation of development of new acquisitions most of the 2020 cost containment measures in 2021 and beyond • Larger contribution from SRAAS

Solid Fundamentals: 2021 still some challenges. 2022 back on track

- 178 - 2021 Investor & Analyst Day June 21

3 Key Drivers to Support Further Growth and Profitability

- 179 - 2021 Key Drivers to Support Further Growth and Profitability Investor & Analyst Day Fit for Growth June 21

Structural Virtuous Cycle costs optimization plan R&D SG&A Divest non-strategic Innovation business lines

Net Revenue Profitability Gross Margin

Deleveraging

- 180 - 2021 Cost Optimization and Divest Non-Strategic Lines Investor & Analyst Day Resetting Cost Base to Promote Innovation June 21

Structural Cost Optimization Plan Divest Non-Strategic Business Lines

• Identified further cost reduction opportunities • Driving improved focus on capital allocation on core divisions/business lines • Maintain EUR c.100m in annual run-rate cost savings • Active efforts to divest non-strategic business • Targeted administrative and support functions, lines as well as other non-strategic activities • Each division will contribute to value creation

Increasing Profitability Through Driving Innovation

- 181 - 2021 Focus on Deleveraging and Securing Liquidity Investor & Analyst 6 Day Strategic Investments Led to a Higher Leverage Ratio June 21

5,5

5.1 BPL: 0.4x 5 4.8 4.8 Kedrion: 0.1x Leverage 4.6 ratio 4.5 4.5 Alkahest: 0.2x 4.4 4.4 4,5 4.3 4.3 Gigagen: 0.1x 4.2 4.1 4.1 Green Cross: 0.3x Target 4 4.0x COVID impact 3,5 1Q2018 2Q2018 3Q2018 4Q2018 1Q2019 2Q2019 3Q2019 4Q2019 1Q2020 2Q2020 3Q2020 4Q2020 1Q2021

Efforts to reduce debt Debt and leverage ratio without missing strategic Securing liquidity remain a key priority opportunities

- 182 - 2021 Investor & Analyst Day June 21

4 M&A to Support Growth and Profitability

- 183 - 2021 Successful Track Record to Support Growth Investor & Analyst Day Demonstrated Ability to Successfully Expand June 21 €m CAGR 2016-2020 Acquisitions +10% Interstate Blood Bank (IBBI) Hologic, share SRAAS (100%) in NAT unit KedPlasma Novartis (EV $1.85bn) 6 plasma centers in the U.S. Transfusion 5,340 Diagnostic 5,099 Access Biologicals (49%) (EV $1.675bn) 4,487 4,318 Kiro Grifols (90%) 4,050 Talecris 3,935 Haema (100%) Biotest (EV $4.0bn) 3,355 24 plasma centers in the U.S.

2,621 2,742 MedKeeper (100%) 2,303 Alkahest (100%) Green Cross (Korea) Fractionation facility in Canada and 11 centers in the U.S. Alliance with Egyptian government

2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 BPL & Kedrion 32 plasma centers in the U.S. GigaGen (100%) - 184 - 2021 Securing Our Plasma Supply Investor & Analyst Day Consolidating Our Competitive Advantage June 21

Increase Grifols’ plasma supply and expand, diversify and reinforce our plasma-center network

Acquisition of Acquisition of Acquisition of Plasma Supply 11 plasma centers 25 plasma centers 7 plasma centers Agreement in from Green Cross from BPL from Kedrion Hungary Q4 2020 Q1 2021 Q2 2021 Q1 2021 • 11 U.S.-based plasma • 25 U.S.-based • 7 U.S.-based plasma • 7 Hungary-based centers that obtain plasma centers that centers that obtain plasma centers that 350k liters of obtain 1m liters of 240k liters of obtain 120k liters of plasma/year plasma/year plasma/year plasma/year • USD 90 million • USD 370 million • USD 55 million

- 185 - 2021 Enhancing Our Innovation Strategy Investor & Analyst Day Integrating Alkahest and GigaGen June 21

Diversifying and reinforcing our pipeline by exploring solutions beyond plasma in order to accelerate our plan for sustained margin expansion

Acquisition of the remaining Acquisition of the remaining 55% equity of GigaGen 56% stake of GigaGen September 7, 2020 March 9, 2021

• Its protein-targeted assets and • Acquisition of the remaining non-plasma derived 56% share capital of the U.S. therapeutics projects can help biopharmaceutical company Grifols diversify while retaining its • USD 80 million focus on the science of plasma • USD 146 million

- 186 - 2021 Global Expansion Through New Business Models Investor & Analyst Day Canada, Egypt and China Lead the Way June 21

Multi-level approach to enter new markets and become a reliable long-term partner while helping countries bolster their self-sufficiency

Strategic alliance with the Egyptian government November 24, 2020 Closing of the acquisition of Green Cross fractionation plant in Canada October 1, 2020

• Fractionation plant with a 1.5m-liter • Strategic agreement to develop the local annual capacity and two purification plasma-derived therapies market by opening plants 20 plasma centers and building production facilities in Egypt • Grifols is now the only large-scale commercial manufacturer of plasma • The plasma centers will initially collect around products in Canada 600k liters plasma/year. The plant will have a fractionation capacity of up to 1m liters/year • USD 370 million

- 187 - 2021 SRAAS Continues to Outperform Investor & Analyst Day Delivering Solid Performance June 21 SRAAS + Grifols Bioscience in China1 ($M) SRAAS ($M) Revenue Trend EBITDA and Net Profit Trend Operating Cash Flow

Grifols Bx China 200 200 EBITDA 300 SRAAS Net Profit 747 150200 657 150 202 100 466 88 100 100 188 0 179 149 -100 126 50 102 50 -200 -220 38 0 -3000 2018 2019 2020 2018 2019 2020 2018 2019 2020 P&L Variations

• Unparalleled short-, mid- and long-term growth opportunity Variation Variation ($M) 2019 vs. 2018 2020 vs. 20192 • China is Grifols’ third-largest sales market, representing its leading market for albumin and third most important market for the Diagnostic Division Revenue 374 +43% 422 +7% • High potential for value creation thanks to synergies EBITDA 149 +45% 188 +20% • Strong cash flow generation; no debt Margin 40% 45%

• SRAAS has become the exclusive distributor of Grifols’ plasma-derived Net Profit 88 +$307m 202 +118% products in China, with a robust sales network of 500+ distributors Margin 24% 48%

- 188 - 1 Includes China, Hong Kong SAR, Taiwan and Macao SAR; 2 Growth rate based on currency consistency assumption 2021 Enhancing Investor Communications Investor & Analyst Day June 21

Fluid and Transparent ESG Earnings Releases Communications

Clear focus on ESG and Fluid and transparent In light of the recently issued integrated reporting communications are norm by the Spanish Law Further promote our crucial, especially during and embraced by the transparency on these unprecedented times Spanish Stock Exchange ESG-oriented initiatives Grifols is intensifying its (CNMV) and the fact that efforts to maintain a Grifols’ performance is not Recognized among the quarterly driven, the world’s most sustainable reinforced constant dialogue with stakeholders company will henceforth companies: DJSI, Euronext release its earnings results Vigeo, FTSE4Good, on a half year basis Bloomberg Gender Equality Index and S&P Global Ratings

- 189 - 2021 Key Takeaways Investor & Analyst Day Driving Resource Allocation to Support Further Growth and Profitability June 21

Active efforts to divest Streamlined focus on value Increasing profitability non-strategic line of creation fundamentals through driving innovation businesses

Successful track record of Clear focus on ESG and Deleveraging and liquidity organic and inorganic integrated reporting remain a key priority growth Half Year earnings release

- 190 - 2021 Investor & Analyst Day June 21

Environmental, Social and Governance

Shaping the Industry’s Sustainability Standards

Thomas Glanzmann – Vice-Chairman of Grifols’ Board of Directors and Chairman of Grifols’ Sustainability Committee Nuria Pascual – VP Corporate Treasury & Investor Relations Officer

- 191 - 2021 Investor & Analyst Day June 21

1 Building on Our Heritage to Foster Sustainability as a Strategic Pillar

- 192 - 2021 Sustainability in Our DNA Since 1909… Investor & Analyst Day Built Historically on Our Strong Corporate Values June 21

1st anti-Rh Transfusion 1st Private blood hyperimmune Plasma exchange + Hyperimmune Flebula for indirect & plasma bank globulin to prevent albumin as treatment globulin to treat blood transfusions in Spain blood incompatibility for Alzheimer’s Ebola

1928 1945 1969 2004 2016

1909 1943 1951 1989 2014 2020

Plasma lyophilization Plasmapheresis Plasma double virus Blood & plasma Tests & specific and preparation of development, inactivation, coagulation screening: pathogen plasma therapies freeze-dried plasma for facilitating plasma factors for hemophilia testing with NAT for SARS-CoV-2 transfusion (Spain) collection & plasma Technology therapies

Innovation & Pride Safety Effort Commitment Excellence Teamwork Improvement Our Core Values - 193 - 2021 … Strengthened Through Our Governance Investor & Analyst Day Commitment Based on Ethical Leadership and Internationally Recognized June 21

Definition and approval Board of of sustainability Sustainability Policy Directors strategies, policies + and practices Reinforce our fundamental Principles and commitments regarding our ESG responsibility

2020 • Establish the core principles and Appointments & commitments regarding environmental, social Audit Remuneration Sustainability and governance issues in our business model Committee Committee Committee • Supervise the integration of financial and non-financial information in ESG initiatives

Sustainability Executive Committee

Led by Investor Relations

Promote a well managed and coordinated sustainability strategy at all organizational levels

- 194 - 2021 Integrating Sustainability in Our Strategy Investor & Analyst Day On the Path Towards 2030 and Beyond Led by Our 4 Pillars June 21 Commitment to patients, plasma and plasma donors and bioethics Sustainability Plan grounded on 4 pillars 2030 Talent pool Climate change strategy Commitment with patients and donors

Social impact

Environmental responsibility Waste recovery Attracting and and eco- retaining talent, efficiency occupational health and safety Economic performance and welfare

- 195 - and innovation 2021 Investor & Analyst Day June 21

2 Sustainability Plan: Our Commitments

- 196 - 2021 Sustainability Plan: Our Commitments Investor & Analyst Day June 21

Commitment to Impact on Environmental Our People Donors and Society responsibility Patients

- 197 - 2021 Our People Is Our Top Priority Investor & Analyst Day Our Commitment Promotes Equality, Diversity, Inclusion and Development June 21

Ensure the ongoing Continued efforts to Offer a professional improvement of its promote effective development fostering occupational health, equality continuous training well-being and safety

Encourage teamwork Offer competitive pay to drive innovation by Reflect a diverse and packages and properly sharing insights and inclusive company compensate employees experiences

- 198 - 2021 Our People Is Our Top Priority Investor & Analyst Day Equal Opportunities, Diversity and Professional Development June 21

Workforce at Grifols Ongoing efforts to effectively promote equality

2.2% 23,655 employees U.S. Gender 3.1% 62% Pay Gap of promotions are Spain women 1.3% 60% 40% Germany

Diverse and inclusive company Professional development model focused on strengths and areas for growth

nationalities 88 2 M 99 hours Training average per Hours person Continuous training adapted to the 64% 36% needs of each employee

- 199 - 2021 Commitment to Donors and Patients Investor & Analyst Day Ensuring Non-Discrimination and Donor Health, Safety and Well-Being June 21

No distinction is made Non-discrimination on Compensation policy with regard to the the basis of gender, applies equally to volume of plasma race, ethnicity or all donors collected or donors’ socioeconomic status weight

Our donation centers Same quality and Protecting the health, adhere to the highest safety criteria applied safety, well-being and quality and safety in all Grifols plasma dignity of plasma standards to guarantee centers and for all donors is critical donors donors’ health

- 200 - 2021 Commitment to Donors and Patients Investor & Analyst Day Grifols’ Commitment to Patients is Based on Three Pillars June 21

Awareness campaigns to highlight the role of plasma Price-setting policy grounded on two core principles: Promoting patient engagement • Cost should never be an obstacle by offering up-to-date information 1 to receiving optimal treatment about plasma-collection efforts Collaborations Access to 2• Price should guarantee long-term and Programs treatments Advocacy initiatives to help sustainability and reinforce patients receive access to commitment to innovate plasma-derived treatment PatientCare programs Comprehensive Production capacity >€11 m of plasma-derived support programs and supply medicines donated in 2020 commitment

Grifols has made strategic investments in recent years to increase its access to plasma and led other initiatives to ensure an uninterrupted supply of plasma-derived medicines throughout 2020

- 201 - 2021 Commitment to Donors and Patients Investor & Analyst Day Our Sustainable Business Model Pursues Social Value June 21

€6.2bn 2.1x Total Social Value Impact Social Value Ratio

Donors Community Patients (1)

€1,828M €722M €3,636M

Physical and Educational psychological Healthcare access expenses well-being Improvement in Economic impact Quality of Life Financial stability Healthier lives in donor communities

- 202 - (1) Corresponds to the high end of the sensitivity analysis performed 2021 Our Contribution to Social Progress Investor & Analyst Day Social Action Plan June 21

Education Local Development

Help promote access to education and equality of Build close ties in donor communities and opportunities in communities where Grifols operates areas where production facilities are located

Contribute to driving positive change: gender Community programs in other countries equality, ethics and values and humanitarian aid

Health and Well-being Environment

Promote and improve access to healthcare Contribute to recover and enhance natural and environmental patrimony Direct and foundation-led initiatives Direct initiatives and joint projects in Promote science as a driver of positive change collaboration with nature conservation

- 203 - associations 2021 Our Contribution to Social Progress Investor & Analyst Day Creating Value Beyond Financial Performance June 21 Grifols’ Socio-Economic Contributions

2015-2020 2020

€7.5bn Total economic impact +15% Total economic growth €43bn impact Grifols’ contributions double its impact in x1.8 the U.S. economy

140k Total jobs +42% New jobs growth +44k Grifols generates 6.1 jobs in the U.S. for X6.2 every one job it creates

- 204 - 2021 Environmental Responsibility Investor & Analyst Day Our Six Commitments for 2030 June 21

Emissions Reduction Energy Efficiency Renewable Energies

Reduce greenhouse gas Increase energy Consume 70% of emissions per unit of efficiency electricity from renewable production by per unit of production sources 40% 15% 70%

PROGRESS PROGRESS PROGRESS IN 2020 20% IN 2020 63% IN 2020 5.4%

Decarbonization Circular Economy Protect Biodiversity

Facilitate Continue to implement Protect biodiversity and

decarbonization in measures in every stage promote CO2 capture business travel and of the operational on our properties employee commutes life cycle through the Grifols Wildlife Program

- 205 - 2021 Key Takeaways Investor & Analyst Day Shaping the Industry’s Sustainability Standards June 21

Since our beginnings in 1909, Our commitment promotes Non-discrimination and we have continually equality, diversity, inclusion measures to ensure donors’ strengthened our commitment and talent development health, safety and well-being to generate social impact

Supporting patients through Significant progress access to treatment, Creating social value beyond on 2030 environmental awareness campaigns and financial performance targets support programs

- 206 - 2021 Investor & Analyst Day June 21

Final Remarks

Innovation at the Core of Our Decisions to Drive Profitable Growth

Víctor Grífols Deu – Co-CEO

- 207 - 2021 Excelling in Grifols’ Core Pillars Investor & Analyst Day Since 2005, We Have Excelled in 3 Core Pillars Leading to a 10 Fold Growth June 21

Focus in excelling in 3 out of 4 pillars x10 5,340

Plasma Procurement

Engineering & Manufacturing Talecris acquisition

IPO Commercialization / Global Expansion

524 Innovation 2005 2010 2015 2020

- 208 - 2021 A Solid Basis Investor & Analyst Day Emerging Stronger From the Pandemic; Results to Start Paying Off in the Short-term June 21

Recent activity to reinforce core business Margin improvement

+2 plasma center Continue with structural Canada +7 plasma costs alliance centers optimization plan

+43 plasma + SRAAS centers partnership Divest JV Egypt (+20 centers1) non-strategic business lines

Expanding innovation Increasing plasma Expanding globally & ecosystem with new supply evolving industry and powerful (~80 centers2) paradigm platforms

- 209 - 1 10 of 20 centers to be opened during 2021; 2. Total DCs opened from 2020 Q4 until end of 2021 2021 Innovation Investor & Analyst Day Collecting Results From New Innovation Approach While Paving the Way for the Future June 21

Recent innovation results Foundations for innovation as growth engine

50% of 2020 growth … New Scientific Innovation Organization Internal plasma innovation

Plasma Expand towards a holistic approach in innovation + our core therapeutic areas out licensed (Internal, External, Plasma, Non-plasma) Non-plasma innovation in licensed Powerful legacy & promising platforms Diagnostics Innovation SARS-CoV-2

… and still in ramp-up stage

- 210 - 2021 Innovation Investor & Analyst Day A Global Ecosystem to Deliver Value in Our Core Therapeutic Areas June 21

New Ecosystem Footprint

Grifols Andorra Internal Hub SF Area, CA Immunology Research New Emeryville, Dublin Düdingen, Switzerland Strategic platforms San Carlos Bioscience Diagnostic LA, San Diego (e.g. Alkahest, Alliances GigaGen) (e.g. Rigel, J&J) & South San Francisco, CA Hub RTP, NC Hub Europa Bioscience Barcelona, Bilbao and and Diagnostic Research Zaragoza, Spain Invested Investigator Triangle Bioscience and Diagnostic sponsored Park, NC companies External Bioscience (e.g. Araclon, research AlbaJuna) research collaborations (e.g. Universities, public & private institutions) +1,100 employees

Therapeutic areas Immunology Neurology Pulmonology & Infectious Diseases Hepatology Hematology Ophthalmology New & Intensive Care Addition

- 211 - 2021 Innovation Ambition Investor & Analyst Day Innovation to Drive Profitable Growth June 21

Revenues from new product launches

Structural 4% Steady product costs launches optimization plan 20%

Sources to Revenue fund innovation Divesting non-strategic business lines Gross margin

Project prioritization 2020 2030+

- 212 - 2021 Innovation Investor & Analyst Day Moving Forward, Innovation Will Be the Engine of Profitable Growth June 21

Innovation

Short – mid term Long term Stronger & resilient Commercialization / infrastructure Innovation as Global Expansion to deliver on an engine of short term profitable Harvesting growth Engineering & Manufacturing recent innovation results Plasma Procurement Leading in industry paradigm evolution

2005 2020 2030 + - 213 - 2021 Investor and Analyst Day

June 3, 2021 2021 Investor & Analyst Day June 21

Glossary

- 215 - 2021 Glossary Investor & Analyst Day June 21 • Alpha-1 antitrypsin deficiency (AATD): Inherited disease characterized by low levels of, or no,alpha-1 antitrypsin (AAT) in the blood. This protein made in the liver, reaches other organs (such as the lungs), after being released into the blood stream, enabling its normal function. • Albumin: The most abundant protein found in plasma (approximately 60% of human plasma). Produced in the liver, it is important in regulating blood volume by maintaining the oncotic pressure of the blood compartment. • Alzheimer’s disease (AD): This is the most common form of dementia. This incurable, degenerative, and terminal disease was first described by German psychiatrist and neuropathologist Alois Alzheimer in 1906 and was named after him. • American Society for Apheresis (ASFA): An organization of physicians, scientists, and allied health professionals whose mission is to advance apheresis medicine for patients, donors and practitioners through education, evidence-based practice, research and advocacy • Autoimmune disease: Condition in which the immune system mistakenly attacks healthy cells. • Babesiosis/Babesia virus: Disease caused by microscopic parasites that infect red blood cells. • Beta-amyloid: Protein strongly implicated in Alzheimer’s diseases. Beta-amyloid is the main component of certain deposits found in the brains of patients of Alzheimer’s disease. • CIDP (Chronic Inflammatory Demyelinating Polyneuropathy): Neurological disorder which causes gradual weakness, numbness, pain in arms and legs and difficulty in walking. • Cirrhosis: Medical condition which is a result of advanced liver disease. It is characterized by there placement of liver tissue by fibrosis (scar tissue) and regenerative nodules (lumps that occur due to attempted repair of damaged tissue). • Chronic Lymphocytic Leukemia (CLL): a type of cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made • COVID-19: Infectious disease caused by a new strain of coronavirus. ‘CO’ stands for corona, ‘VI’ for virus, and ‘D’ for disease. • ELISA: Enzyme-linked immunosorbent assay. • EMA: European Medicines Agency. • EPCM: Engineering, Procurement, Construction Management. • Factor VIII or FVIII: This is an essential blood clotting factor also known as anti-hemophilic factor(AHF). In humans, Factor VIII is encoded by the F8 gene. Defects in this gene results in hemophilia A, a sexlinked disease that occurs predominantly in males. FVIII concentrated from donated blood plasma, or alternatively recombinant FVIII, or rFVIII can be given to hemophiliacs to restore hemostasis. - 216 - 2021 Glossary Investor & Analyst Day June 21 • Factor IX: This is an important blood clotting factor also known as Christmas factor or plasma thromboplastin component (PTC). It is one of the serine proteases of the coagulation system and belongs to the peptidase family S1. In humans, a deficiency of this protein causes hemophilia B, a sex-linked disease that occurs predominantly in males. • FDA: Food and Drug Administration. U.S. Health Authority. • Fibrin sealant: Surgical adhesive material derived from plasma. • Fibrinogen: Coagulation factor found in human plasma crucial for blood clot formation. • Fractionation: Process of separating plasma into its component parts, such as albumin, immunoglobulin, alpha-1 antitrypsin and coagulation factors. • HBV: Hepatitis B Virus. • HCV: Hepatitis C Virus. • Hematology: The study of blood, blood-forming organs, and blood diseases. • Hemoderivative: Proteins obtained by fractionation of human blood plasma. See plasma derived proteins. • Hemophilia: Genetic deficiency characterized by the lack of one of the clotting factors. It has two main variants: ꟷ Hemophilia A: genetic deficiency of coagulation Factor VIII, which causes increased bleeding (usually affects males). ꟷ Hemophilia B: genetic deficiency of coagulation Factor IX. • Hemotherapy: Treatment of a disease using blood, blood components and its derivatives. • HEOR: Health Economics Outcomes Research • HIV: Human Immunodeficiency Virus. • Hyperimmune globulin: class of immunoglobulins prepared in a similar way as for normal human immunoglobulin, except that the donor has high titers of antibody against a specific organism or antigen in their plasma. • IA: Immunoassays. These are systems available in several formats that may be used to detect antibodies, recombinant proteins or a combination of the two. • Immunoglobulins: Also known as antibodies, are proteins derived from plasma. They control de body’s immune response. They have multiple indications and some of their main uses are to treat: (i) immune deficiencies, (ii) inflammatory and autoimmune diseases and (iii) acute - 217 - infections. IVIG is an immunoglobulin administered intravenously that contains IgG (immunoglobulin (antibody) G). 2021 Glossary Investor & Analyst Day June 21 • Intravenous: Administration of drugs or fluids directly into a vein. • Immunohematology: A branch of hematology related to the study of recombinant proteins and antibodies and their effects on blood and the relationships between blood disorders and the immune system. Also referred to as Transfusional Medicine – blood bank, its main activities include blood typing, compatibility tests and crossmatching and antibody identification. • Immunology: This is a branch of biomedical science that covers the study of all aspects of the immune system in organisms. It deals with the physiological functioning of the immune system in states of both health and disease; malfunctions (autoimmune diseases, hypersensitivities, immune deficiency, transplant rejection) and the physical, chemical and physiological characteristics of the components of the immune system in vitro, in situ, and in vivo. • Immunoglobulin (IgG): Also known as antibodies, are proteins derived from plasma. They control de body’s immune response. They have multiple indications and some of their main uses are to treat: (i) immune deficiencies, (ii) inflammatory and autoimmune diseases and (iii) acute infections. IVIG is an immunoglobulin administered intravenously that contains IgG (immunoglobulin (antibody) G). • ITP (Chronic immune thrombocytopenia): Autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets. This results in a low blood platelet count (thrombocytopenia) that may produce bruising or excessive bleeding. • IVD: In vitro Diagnostic. • IV solutions/Intravenous solution: Medicine or homogeneous mixture of a substance in liquid, enabling it to be infused into the circulatory system through a needle. • Molecular Diagnostics: Discipline that studies genomic (DNA) and proteomic (proteins)expression patterns and uses the information to distinguish between normal, precancerous, and cancerous tissues at the molecular level. • Monoclonal antibody (mAb): Antibody produced by a single clone of cells typically used in immunotherapy (such as in the treatment of autoimmune or inflammatory disorders and cancer), diagnostic testing and cell identification and tracing. Monoclonal antibodies are a cornerstone of immunology and are increasingly coming into use as therapeutic agents. • Myasthenia Gravis (MG): Chronic autoimmune, neuromuscular disease that causes weakness in the skeletal muscles that worsens after periods of activity and improves after periods of rest. These muscles are responsible for functions involving breathing and moving parts of the body.

- 218 - 2021 Glossary Investor & Analyst Day June 21 • NAT: Nucleic Acid Amplification Testing. • Neovascular Age-Related Macular Degeneration (nAMD): is a disease that impacts the central area of the retina in the eye, called the macula. • Neurology: Science that deals with the anatomy, functions and organic disorders of nerves and the nervous system. • Ophthalmology: is a branch of medicine and surgery that deals with the diagnosis and treatment of disorders of the eyE • Pandemic: The worldwide spread of a new disease. • PCR: Polymerase chain reaction is a method widely used to rapidly make millions to billions of copies of a specific DNA sample, allowing scientists to take a very small sample of DNA and amplify it to a large enough amount to study in detail. • pdFVIII: Plasma-derived Factor VIII. • Parkinson Disease Dementia (PDD): complex neurodegenerative disorder where each patient experience different combination of motor and non-motor symptoms • Pharmacovigilance: Practice of monitoring the effects of medical drugs after they have been licensed for use, especially in order to identify and evaluate previously unreported adverse reactions. • Plasma: Yellow-coloured liquid part of the blood, consisting of a mix of a large number of proteins in solution. • Plasma-derived proteins: Purified plasma proteins with therapeutic properties that are obtained through the fractionation of human plasma. Albumin, immunoglobulins, factor VIII and alpha-1 antitrypsin are the main plasma proteins. • Plasmapheresis: Plasmapheresis is a technique which separates plasma from other blood components, such as red blood cells, platelets and other cells. These unused blood components are suspended in saline solution and immediately reinjected back into the donor. Because the donor is only providing plasma and not whole blood, the recovery process is faster and better tolerated, and the donor is able to make donations more frequently. Plasmapheresis was developed by Jose Antonio Grifols Lucas in the year 1951. It is the only procedure that is capable of obtaining sufficient quantities of plasma to cover the manufacturing needs for the different plasma protein therapies. • Plasma Proteomics: is a term which describes the high-throughput analysis of plasma biomarkers using very powerful, sensitive and specific instruments. • PPTA: Plasma Protein Therapeutics Association. • Primary immunodeficiency (PID/PIDD): Inherited condition where there is an impaired immune response, weakening the immune system and - 219 - allowing infections and other health problems to occur more easily. It may be in one or more aspects of the immune system. 2021 Glossary Investor & Analyst Day June 21 • ProlastinR/ProlastinR -C: This is a concentrated form of alpha-1 antitrypsin (AAT), derived from human plasma and approved only for chronic, or ongoing, replacement therapy in people with genetic AAT deficiency. Given as prescribed, Prolastin raises the levels of AAT in the blood and lungs. Raising the AAT level may help reduce the damage to the lungs caused by destructive enzymes. • Pulmonology: is an area of medicine that focuses on the health of the respiratory system. Pulmonologists treat everything from asthma to tuberculosis. • Recombinant: Protein prepared by recombinant technology, coded by the manipulated gene. Procedures are used to join together segments in a cell-free system (an environment outside a cell organism). They are known as highly potent medicines that are safe from off-target side effects and take a shorter time to develop than small molecules. • rFVIII: Recombinant Factor VIII is the antihemophilic factor A, obtained using recombinant DNA technology. With this technology, pure factor is synthesized in the laboratory instead of being extracted from blood plasma. • ROW: Rest of the World. • SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2 is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. • Secondary immunodeficiency (SID) : Occurs when the immune system is compromised due to an environmental factor. Examples of these outside forces include HIV, chemotherapy, severe burns or malnutrition. • SCIG: Subcutaneous Immunoglobulin • Thrombin: Enzyme that presides over the conversion of a substance called fibrinogen to fibrin, which promotes blood clotting. • Transfusion medicine: Branch of medicine that encompasses among others, immunohematology, blood and plasma screening and blood typing. • West Nile Virus (WNV): Virus transmitted by mosquitoes. Humans are mainly infected through mosquito bites, but infection can occur through organ transplantation and blood. • Von Willebrand Disease (vWD): This is the most common hereditary coagulation abnormality described in humans, although it can also be acquired as a result of other medical conditions. It arises from a qualitative or quantitative deficiency of von Willebrand factor (vWF), a multimeric protein that is required for platelet adhesion. • Zika virus: Infectious disease spread by the bite of an infected Aedes species mosquito.

- 220 -